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The Open Source Biotechnology Movement: Is It
Patent Misuse?
Robin Feldman*
INTRODUCTION
In the field of biotechnology, fledgling efforts are under
way to establish open source projects.1 Borrowing concepts
from the open source software movement, these projects create
cooperative exchanges in which life science inventions are
openly available to a broad research community.2 The projects
* Assistant Professor, U.C. Hastings College of the Law. I am grateful
to Margreth Barrett, Dan Burk, Larry Lessig and Brad Rosenblatt for their
comments on prior drafts. I am also indebted to Amy Hsaio and Charlie Chou
for their research assistance.
1. See Stephen M. Maurer et al., Finding Cures for Tropical Diseases: Is
Open Source an Answer?, in BIOTECHNOLOGY: ESSAYS FROM ITS HEARTLAND
33, 33-36 (Lynn Yarris ed., 2004) (discussing convergence of computing,
biology,
and
open
source
for
drug
discovery),
available
at
http://www.bayeconfor.org/pdf/BioTechReport.pdf; see also ABOUT THE
INTERNATIONAL HAPMAP PROJECT [hereinafter HAPMAP PROJECT] (promoting
utilization of open source techniques in developing a haplotype map of the
human genome), at http://www.hapmap.org/abouthapmap.html (last modified
June 4, 2004); BIOINFORMATICS.ORG, 2002 ORGANIZATION PLAN (explaining
the mission of Bioinformatics.Org is “providing free and open resources for
research, development and education”), at http://bioinformatics.org/about/plan20020920.pdf (Sept. 20, 2002); Pamela Jones, Interview: Public Patent
Foundation's Dan Ravicher (explaining the Public Patent Foundation’s goal of
developing a system of protected commons for markets that are hampered by
the presence of so many patent rights that it is difficult for researchers to
operate), at http://lwn.net/Articles/64378/ (Dec. 23, 2003); Graeme O’Neill,
‘Open-Source Biology’ Stance Earns International Honour, AUSTRALIAN
BIOTECHNOLOGY
NEWS
(describing
BIOS),
at
http://www.cambia.org/downloads/Biotechnology_News_Dec_03.pdf (Mar. 12,
2003); Anna Salleh, Push to Free up Biotech Tools for All, ABC SCIENCE
ONLINE (describing plans to assemble groups of enabling technologies that
together provide the pieces necessary for a particular form of research
investigation), at http://www.abc.net.au/science/news/stories/s999733.htm
(Dec. 1, 2003). See generally An Open-source Shot in the Arm?, ECONOMIST,
June 10, 2004, at 17 (discussing open source in biotechnology), available at
http://www.economist.com/displaystory.cfm?story_id=2724420.
2. See, e.g., HAPMAP PROJECT, supra note 1 (describing the HapMap
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are aimed at solving problems in underserved communities,
cutting through patent thickets, and ensuring that the
biotechnology tools required for research and innovation are
openly available.3
Building on the software notion of “copyleft,” some open
source biotechnology projects use the power of the patent
system to ensure that the core technology of the project and any
innovations remain openly available. For example, under
ordinary principles of patent law, those who make
improvements in the core technology would be entitled to apply
for patent rights on the improvements.4 As the technology
advances, these improvement patents could lead to rights
splintering in which so many people hold pieces of rights to a
particular technology that access is hindered. In response to
this problem, open source biotechnology projects often require
participants to agree that advances in the technology must
remain as openly available as the original technology.5
Such agreements may implicate the doctrine of patent
misuse. Patent misuse is defined as an impermissible attempt
to expand the time or scope of the patent beyond the patent
grant.6 It includes attempts to expand the patent power to
things not included in the teachings of the original patent.
Improvements in the core technology may not be within the
teachings of the original patent. Thus, when open source
Project’s goal of ensuring biotechnology tools are openly available).
3. See id.; Jones, supra note 1; see also Maurer, supra note 1.
4. See Gen. Elec. Co. v. Wabash Appliance Corp., 304 U.S. 364, 368
(1938) (noting “most inventions represent improvements on some existing
article, process or machine”); Chiron Corp. v. Genentech, Inc., 268 F. Supp. 2d
1148, 1155 (E.D. Cal. 2002) (“Patents are and should be granted to later
inventors upon nonobvious improvements.”), reh’g denied, 2004 U.S. App.
LEXIS 12762 (Fed. Cir. 2004).
5. See, e.g., INTERNATIONAL HAPMAP PROJECT PUBLIC ACCESS LICENSE,
[hereinafter PUBLIC ACCESS LICENSE] (requiring that users agree to not
reduce others' access to the data and to share the data only with others who
have made the same agreement), at http://www.hapmap.org/cgiperl/registration#liTerms (Aug. 2003); see also O’Neill, supra note 1
(explaining users agree to grant back any improvements in the core technology
and to make such improvements freely available to all others on the same
terms that BIOS provided for the original core technology).
6. See Blonder-Tongue Labs., Inc. v. Univ. of Ill. Found., 402 U.S. 313,
343 (1971) (noting that the Court has condemned attempts to broaden the
physical or temporal scope of the patent monopoly), remanded on other
grounds, 334 F. Supp. 47 (N.D. Ill. 1971), affd, 465 F.2d 380 (7th Cir. 1972),
cert. denied, 409 U.S. 1061 (1972); see generally 6 DONALD S. CHISUM, CHISUM
ON PATENTS § 19.04 (2003) (discussing patent misuse).
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biotechnology licenses require that advances in the technology
must be made available to others on the same open terms as
the original technology, the open source group may be using the
power of the patent grant to reach an invention outside the
original patent. When a patent holder appears to expand the
scope of the patent beyond the patent grant, the question is
whether the behavior is impermissible, as measured by the
tests within the patent misuse doctrine.
In recent years, the Federal Circuit has revised the
doctrine of patent misuse to mirror the federal antitrust laws.7
The Federal Circuit currently tests for patent misuse by
looking for anticompetitive effects through application of the
antitrust rule of reason.8
Despite the Federal Circuit’s recent focus, relevant
legislative and judicial precedents suggest that patent misuse
should be tested by reference to patent policy and not antitrust
law.9 Under this approach, patent misuse in open source
biotechnology arrangements would be evaluated based on
whether the effects of the behavior are inconsistent with patent
policy. This article applies both of these tests to determine
whether open source arrangements should be considered patent
misuse.
The primary goal of the patent system is to promote the
progress of science for the public benefit.10 As the United
States Supreme Court explained in 1945, “[t]he primary
purpose of our patent system is not reward of the individual
but the advancement of the arts and sciences. Its inducement is

7. See Robin C. Feldman, The Insufficiency of Antitrust Analysis for
Patent Misuse, 55 HASTINGS L.J. 399, 421-31 (2003) (discussing development
of the law in the Federal Circuit).
8. See, e.g., Mallinckrodt, Inc. v. Medipart, Inc., 976 F.2d 700, 708 (Fed.
Cir. 1992) (holding that in a patent misuse inquiry, the appropriate criterion is
whether the patent holder has ventured beyond the patent grant and into
behavior having an anticompetitive effect not justifiable under the rule of
reason); see also Va. Panel Corp. v. MAC Panel Co., 133 F.3d 860, 868-69 (Fed.
Cir. 1997) (evaluating Mallinckrodt, Inc. criteria and identifying certain
practices constituting per se patent misuse), cert. denied, 525 U.S. 815 (1998);
C.R. Bard, Inc. v. M3 Sys. Inc., 157 F.3d 1340, 1372 (Fed. Cir. 1998)
(evaluating Mallinckrodt, Inc. criteria), reh’g denied 161 F.3d 1380 (Fed. Cir.
1998), cert. denied, 526 U.S. 1130 (1999); B. Braun Med., Inc. v. Abbott Labs.,
124 F.3d 1419, 1426 (Fed. Cir. 1997) (evaluating Mallinckrodt, Inc. criteria);
Bayer AG v. Housey Pharm., Inc., 228 F. Supp. 2d 467, 469 (D. Del. 2002)
(applying the Federal Circuit test), aff’d, 366 F.3d 1348 (Fed. Cir. 2004).
9. See Feldman, supra note 7.
10. See U.S. CONST. art. I, § 8, cl. 8.
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directed to disclosure of advances in knowledge which will be
beneficial to society; it is not a certificate of merit, but an
incentive to disclosure.”11 To accomplish this ultimate goal, the
patent system encourages innovation by granting inventors
limited rights to exclude others from their invention.12 The
patent system grants these rights recognizing that there may
be undesirable effects in the short run which will be offset by
the system’s ability to spur innovation over the long run.13
As a general matter, the open source system is consistent
with patent policy.
Accelerating the moment at which
knowledge is widely available is consistent with patent policy’s
design to bring inventions into the public domain for the public
benefit.
On a more detailed level, however, the open source system
threatens to clash with patent policy. The patent system uses
economic rewards to promote invention. If the open source
system reduces the economic reward available to downstream
inventors, this reduction may decrease the amount of long-term
innovation. A decrease in long-term innovation would be
inconsistent with patent policy.
Such an analysis, however, fails to consider all of the
effects throughout the system across time. Although open
source biotechnology may decrease some downstream economic
returns, it increases downstream non-economic rewards. In
addition, open source licensing may increase the level of
downstream innovation by encouraging the exploitation of
certain types of untapped. Finally, open source arrangements
decrease the harms of the current patent system by reducing
patent thickets and avoiding the short-term restriction of
supply that one would expect under traditional patent
licensing. For example, in granting a patent, the patent

11. Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 330-31
(1945).
12. See Kewanee Oil v. Bicron Corp., 416 U.S. 470, 480 (1974) (explaining
that the patent laws carry out the Constitutional mandate to “promote this
progress by offering a right of exclusion for a limited period as an incentive to
inventors to risk the often enormous costs in terms of time, research, and
development”).
13. See Jay P. Kesan & Marc Banik, Patents as Incomplete Contracts:
Aligning Incentives for R&D Investment with Incentives to Disclose Prior Art, 2
WASH. U. J.L. & POL'Y 23, 23-24 (2000) (noting that patents “impose social
costs such as reduced levels of competition or wasteful design-around efforts
by competitors” but also create an incentive to invest in research and
development that leads to innovation).

2004]

OPEN SOURCE BIOTECHNOLOGY

121

holder’s ability to exclude others from making, using, or selling
the invention will suppress competition and restrict supply of
the invention, at least during the patent term.14 Open source
inventions, which are openly available from the start, do not
create the same type of restriction of supply. The overall effect
of the open source system is to increase the supply of
innovation and the speed at which such innovation is available
for the public benefit, effects that are consistent with patent
policy.
If patent misuse is analyzed by testing for anticompetitive
effects under the antitrust rule of reason, the results would be
the same although the logic would differ at some points.
Finding anticompetitive effects under the rule of reason
requires finding market power, anticompetitive effects, and
proof that the anticompetitive effects outweigh any procompetitive benefits.15
Many open source products would not have market power
in a properly defined market, given the availability of
substitutes. For example, the open source software Linux does
not have market power in the operating system market given
competition from other operating systems such as Windows. If
an open source group did possess market power, any
anticompetitive effects of open source would have to be weighed
against the pro-competitive effects.
One might argue that open source arrangements could be
characterized as an attempt by the original open source group
to prevent the development of a downstream product that
would be available on different terms. Such behavior could be
described as an attempt to reduce competition, which could
restrict supply in relevant markets. Behavior that restricts
supply may be considered anticompetitive under the antitrust
rule of reason.
The open source group, however, is not trying to restrict
the supply of available products. It is trying to increase the
supply of biotech tools that are available by ensuring that the
14. See Kenneth J. Arrow, Economic Welfare & the Allocation of Resources
for Invention, in THE RATE AND DIRECTION OF INVENTIVE ACTIVITY: ECONOMIC
AND SOCIAL FACTORS 609, 617 (Nat’l Bureau of Econ. Research ed., 1962)
(noting that patent rights produce underutilization of information).
15. See Bd. of Trade v. United States, 246 U.S. 231, 238 (1918) (“Every
agreement concerning trade, every regulation of trade, restrains . . . . The true
test of legality is whether the restraint imposed is such as merely regulates
and perhaps thereby promotes competition or whether it is such as may
suppress or even destroy competition.”).
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tools in their most advanced incarnation remain openly
available. Thus, the effects of the open source system are
better characterized as increasing rather than reducing the
supply of relevant products.
Finally, any anticompetitive effects of the open source
behavior would be outweighed by the pro-competitive effects of
reducing patent thickets and promoting the creation and
dissemination of ideas without a short-term restriction of
supply. Thus, the effects of the open source biotechnology
system should not be considered anticompetitive under the
antitrust rule of reason, and therefore should not constitute
patent misuse.
Part I of this article describes the current open source
biotechnology movement and its predecessor, the open source
software movement. Part II describes the doctrine of patent
misuse. Part III compares open source biotechnology licensing
to three traditional patent licensing arrangements: field of use
restrictions, grantbacks, and reach-through royalties.
It
describes how the patent misuse doctrine has been applied to
these arrangements. Part IV examines whether open source
biotechnology practices should be considered patent misuse by
examining whether the effects are inconsistent with patent
policy. Part V considers whether open source should be
considered patent misuse by examining whether the effects are
anticompetitive as measured by the rule of reason. The article
concludes that although open source biotechnology practices
may implicate the doctrine of patent misuse, they should not be
considered misuse under either test.
I. THE OPEN SOURCE BIOTECHNOLOGY MOVEMENT
A. CURRENT OPEN SOURCE BIOTECHNOLOGY PROJECTS
The open source movement in biotechnology offers a
structure for cooperative exchange in the development of life
science products that are either bioengineered or produced as a
result of techniques that involve biotechnology. The projects
and their design are varied, but a common theme is the desire
to make biotechnology advances available to a broad research
community and to ensure that such open access continues.16
16. See, e.g., HAPMAP PROJECT, supra note 1 (explaining that the project
will release all the data it produces so that any researcher can use the
information and that those who are granted access to the information shall not
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The goal of many open source biotechnology projects is to
counteract the phenomenon in certain research areas in which
progress is hampered by the rights structure surrounding basic
investigative tools.17 In some areas, the problem is simply the
multitude of rights. For example, transferring a gene to a crop
plant may require dozens of individually protected and discrete
technologies.18 Thus, a researcher trying to search for effective
ways to genetically alter a particular plant for a particular trait
will have to identify and obtain dozens of separate rights.
Transaction costs are significant for commercial entities and
may be overwhelming for poor nations, academic researchers,
and other nonprofit entities that lack the resources to identify
and negotiate all of the necessary rights.19
Scholars have used the term “patent thicket” to describe
the problem of multiple overlapping rights that can hamper
innovation by creating transaction barriers.20 Most scholars
restrict the access to the Genotype Database or the data that it contains); see
also CAMBIA, PHILOSOPHY GUIDING FUTURE REGISTRATION TO USE THIS SITE
(“CAMBIA's philosophy is to ensure that access to resources, including the IP
Resource,
is
affordable
to
any
and
all
users.”),
at
http://www.cambiaip.org/legal/Terms/Payment_policy.htm (last visited Sept.
11, 2004) O’Neill, supra note 1 (explaining users agree to grant back any
improvements in the core technology and to make such improvements freely
available to all others on the same terms that BIOS provided for the original
core technology thus assuring that a broad research community will have
continued access to those tools).
17. See Kenneth Neil Cukier, Open Source Biotech: Can a Non-proprietary
Approach to Intellectual Property Work in the Life Sciences? (stating the
current
patent
system
is
an
encumbrance),
at
http://www.cukier.com/writings/acumen-cukier-oct03.pdf (last visited Sept. 7,
2004); Jones, supra note 1 (listing “establishing patent commons within
markets crippled by patent thickets” as one purpose of the Public Patent
Foundation); Salleh, supra note 1; see also Rebecca S. Eisenberg, Bargaining
over the Transfer of Proprietary Research Tools: Is this Market Failing or
Emerging, in EXPANDING THE BOUNDARIES OF INTELLECTUAL PROPERTY 223,
225 (Rochelle Cooper Dreyfuss et al. eds., 2001) (noting some scientists must
wait months or even years before gaining access to tools while their
institutions wade through the many patent licensing agreements).
18. See Robin Feldman, CAMBIA BIOS Initiative: Biological Innovation
for Open Society (Mar. 29 2004) [hereinafter BIOS Rockefeller Application]
(unpublished manuscript submitted as an application to The Rockefeller
Foundation) (on file with author).
19. See id.; Cukier, supra note 17, at 56; see also Lita Nelsen, The Rise of
Intellectual Property Protection in the American University, 279 SCIENCE 1460,
1461 (1998) (noting that restricted availability or delays in exchange of
research tools in biological research is a problem for university research).
20. See Carl Shapiro, Navigating the Patent Thicket: Cross Licenses,
Patent Pools, and Standard-Setting, in 1 INNOVATION POLICY AND THE
ECONOMY 1, 1-2 (Adam Jaffe et al. eds., 2001), available at
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and those reporting from the field agree that large numbers of
rights hamper research and innovation, particularly in the
biotechnology field.21 One study, however, has challenged the
notion.22 John Walsh, Ashish Arora, and Wesley M. Cohen
argue that firms simply work around the problem of multiple
rights, for example, by moving offshore beyond the reach of
patent rights, inventing around the rights, and using public
research tools.23 In particular, they argue that academic
researchers routinely ignore rights structures and that patent
holders passively acquiesce.24 These options may not be
available, however, to those with limited resources. Inventing
around a patent and jurisdiction dodging are expensive.
Ignoring rights is a risky enterprise, particularly for those who
have limited resources to defend against a charge of
infringement.
In areas not plagued by patent thickets, basic research
tools may be controlled by one entity or a small group of
entities.25 The cost of accessing these tools may be beyond the
reach of nonprofit researchers and those targeting the problems
of lesser developed nations, problems which are unlikely to
generate great economic rewards.
Some open source biotechnology projects are designed as
cooperative ventures in which a community of scientists works
together to solve a common problem. For example, Stephen
Maurer, Arti Rai, and Andrej Sali have proposed a “Tropical
Disease Initiative” in which scientists from universities,
laboratories, and corporations could work together on earlystage development of drugs to fight tropical diseases.26 The
project would revolve around a web site in which individual
http://faculty.haas.berkeley.edu/shapiro/thicket.pdf.
21. See id.; see also supra notes 17-19.
22. JOHN P. WALSH ET AL., RESEARCH TOOL PATENTING AND LICENSING
AND
BIOMEDICAL
INNOVATION,
at
www.heinz.cmu.edu/wpapers/download.jsp?3d=2003-2 (Dec. 11, 2002); John P.
Walsh et al., Working Through the Patent Problem, 299 SCIENCE 1021 (2003),
(summarizing the lack of impact of upstream patents on research), available
at http://tigger.uic.edu/~jwalsh/WalshetalScience.pdf.
23. See WALSH ET AL., supra note 22, at 41.
24. See id. at 42; see also John P. Walsh et al., supra note 22.
25. See BIOS Rockefeller Application, supra note 18.
26. See Maurer, supra note 2; see also Janet Hope, Open Source
Biotechnology? (2003) (unpublished Ph.D dissertation, Australian National
University) (discussing the potential for application of open source approaches
to biotechnology), at http://rsss.anu.edu.au/~janeth/OSBiotech.html (last
visited Oct. 15, 2005).
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pages would focus on separate tasks such as identifying new
drug targets, searching for new chemicals that affect targets
already identified, and checking the feasibility of existing drugs
on the targets.27 Identifying drug targets involves finding
specific parts of the human molecular structure such as genes
or proteins that play a role in the mechanism of a targeted
disease process.28 For example, the genes that go awry in a
particular cancer are often identified as drug targets in cancer
research because they allow scientists to target the molecular
mechanisms underlying the disease.29 In the Tropical Disease
Initiative project, scientists would annotate a shared database
each time they made a discovery related to the relevant drug
targets, and the results could be discussed in internet chat
rooms and at conferences.30
A similar effort is underway in the HapMap Project, which
is developing a specialized map of the human genome.31 The
goal of the project is to develop a map that describes not the
standard sequence of human DNA but rather common patterns
of human DNA variation.32 The project began in fall 2002 and
is expected to take at least three years to complete.33 The
information generated by the project is freely available,
provided that those who access the data do not restrict the
access of others.34
In particular, users must agree not to file patent
applications for information contained in the database such as
single nucleotide polymorphisms (SNPs).35 SNPs are sites in
27. See Mauer, supra note 1, at 34, 37.
28. See generally Jürgen Drews, Drug Discovery: A Historical Perspective,
287 SCIENCE 1960 (2000) (discussing the development of different types of
drug targets and their uses).
29. See Jackson B. Gibbs, Mechanism-Based Target Identification and
Drug Discovery in Cancer Research, 287 SCIENCE 1969, 1970 (2000); see also
Aimee E. Belanger et al., PCR-Based Ordered Genomic Libraries: A New
Approach to Drug Target Identification for Streptococcus pneumoniae, 46
ANTIMICROBIAL AGENTS & CHEMOTHERAPY 2507, 2507 (2002) (describing the
discovery process of drug targets to cure Streptococcus pneumoniae “by first
determining which of the ordered amplicons yields resistant transformants
and then examining the genetic content of the amplicon in question”),
available at http://aac.asm.org/cgi/content/full/46/8/2507.
30. See Maurer, supra note 1, at 37.
31. See HAPMAP PROJECT, supra note 1.
32. Id.
33. Id.
34. See PUBLIC ACCESS LICENSE, supra note 5.
35. Id.
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the human genome where the DNA sequences of many
individuals differ slightly.36 Users must also agree that any
patents filed for particular uses of the SNPs or other data in
the Genotype Database will be licensed on terms that allow
others free access to the data in the Genotype Database for
other purposes.37
Other projects, such as the Public Patent Foundation
project, are envisioned as protected commons in which patent
holders would agree to pool their technologies, which would
then be freely available to all participants.38 The Public Patent
Foundation plans to develop a system of protected commons for
markets that are hampered by the presence of so many patent
rights that it is difficult for any researchers, even those who
hold patents themselves, to operate.39
In each commons, patent holders would grant nonexclusive
licenses to a public trust that would then make all of the
technologies available to the participants.40 The commons
would operate along the lines of a disarmament treaty that
permits only bilateral participation.41 In other words, one
cannot benefit from the patent commons without placing one’s
rights in the commons as well.42
Another project, the Biological Innovation for Open Society
(BIOS) plans to operate as a combination of the cooperative and
the protected commons approaches.43 BIOS plans to assemble
groups of enabling technologies that together provide the pieces
necessary for a particular form of research investigation.44 For
example, a BIOS group, or node, might contain a core
technology, or groups of technologies, necessary for introducing
new genes into plants. Such technologies would not have to be
superior to existing commercial technologies. They would just
need to provide a sufficiently effective tool for engaging in the
36. See HAPMAP PROJECT, supra note 1 (describing single nucleotide
polymorphisms).
37. See PUBLIC ACCESS LICENSE, supra note 5.
38. See Jones, supra note 1.
39. Id.
40. E-mail from Dan Ravicher, Executive Director, Public Patent
Foundation, to Robin Feldman, Assistant Professor of Law, University of
California Hastings College of the Law (Jan. 13, 2004, 11:34 PST) (on file with
author).
41. Id.
42. Id.
43. Salleh, supra note 1.
44. See id.
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basic research such that developing nations, small
biotechnology companies, and public research agencies will be
able to engage in research without becoming ensnared in
current patent traps.45
BIOS founder Richard Jefferson uses a wheel-and-spoke
analogy to describe his vision of groups of technologies that
enable biotechnology research. According to this analogy,
biological technologies are interdependent, requiring several
key components to function, just as a wheel requires a number
of spokes in order to operate.46 BIOS hopes that it will be able
to provide participants with complete packages including all of
the spokes.47
Although BIOS is in the planning phases, it has access to
some technologies that may help propel its projects. BIOS is an
outgrowth of the Center for the Application of Molecular
Biology to International Agriculture (CAMBIA). BIOS now
holds the rights to CAMBIA’s intellectual property. 48 Such
technology includes D ArT, a patented genotyping, or gene
mapping method, invented by one of CAMBIA’s scientists.49
Other technologies include a method for introducing new genes
into plants such that the resulting proteins will be expressed
only in specific tissues such as roots, flowers, seeds, or leaves.50
This technique bypasses a host of patents that researchers
otherwise would have to navigate and has been successfully
used in a Chinese project to create transgenic rice lines that are
being evaluated for characteristics such as reduced water use
and disease resistance.51
In addition to the technology already developed, BIOS
plans to establish cooperative ventures similar to those
envisioned by Maurer, Rai, and Sali. Individuals and agencies
will be able to collaborate by creating technologies and working
around existing blocks, with BIOS providing the cyberspace
location and the structure for the exchange.52
45. See O’Neill, supra note 1.
46. BIOS Rockefeller Application, supra note 18.
47. See id.
48. See Salleh, supra note 1.
49. See id.
50. See id.; O’Neill, supra note 1.
51. See O’Neill, supra note 1; see also Salleh, supra note 1 (describing
CAMBIA’s work toward developing an alternative to the proprietary
Agrobacterium transformation technology).
52. See BIOS Rockefeller Application, supra note 18; see also Maurer,
supra note 1.
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BIOS technologies will be available free of charge to
anyone.53 Users will be required to sign a license agreeing to
grant back any improvements in the core technology and to
make such improvements freely available to all others on the
same terms that BIOS provided for the original core
technology.54 Without such an agreement, the core technology
could lose its free access as those who improve the technology
apply for proprietary rights to the improvements. Over time,
the core technology would become as encumbered as current
technologies.55
In contrast to improvements to the core research tool
technologies, the BIOS license would permit users to patent
any inventions created. The BIOS founder describes the
license in the following fashion: “‘Th[e] license will say you
agree to share improvements in the core technology. You can
make your own applications as proprietary as you want; you
can patent your invention. But the tools to do that must be a
public good.’”56
Some open source biotechnology projects are centered on
bioinformatics, a type of technology at the intersection of
biology and software. Bioinformatics uses software to generate
and analyze data relating to bioscience research.57 Such
projects tend to follow closely along the lines of their open
source software predecessors.
Software is created and
improved through an unstructured cooperative process.
License agreements frequently mirror those available for open
source software.
For example, several open source
bioinformatics programming languages are available, including
BioPerl, BioJava, Biopython, BioRuby, and others.58 These
languages are available through standard open source software

53. See O’Neill, supra note 1.
54. See id.; Salleh, supra note 1
55. BIOS also plans a database project using its comprehensive publicaccess database that consists of the full text of patents relevant to agricultural
biotechnology, both applications and patents granted, from the United States,
European, and Australian jurisdictions with a user-friendly searchable
interface. See BIOS Rockefeller Application, supra note 18.
56. Salleh, supra note 1.
57. See Edward N. Trifonov, Earliest Pages of Bioinformatics, 16
BIOINFORMATICS 5 (2000) (describing the early development of the field).
58. The Open Bioinformatics Foundation web site exists as a hub for
supporting the languages.
See Open Bioinformatics Foundation,
http://www.open-bio.org (last visited Sept. 15, 2004).
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licenses.59 For example, BioJava is subject to the GNU Lesser
General Public License, a license developed for open source
software.60 The license grants freedom to copy the program,
modify it, and distribute it to others for free or for a fee.61
Among other things, the license requires that those who
distribute or modify the program must make the source code
available to other users and must make modified versions
available on the same terms as the original version.62 Finally,
the license requires that any patent license granted for a
version of the original software must be consistent with the full
freedom of use specified in the original license.63
Most open source biotechnology software projects are
nonprofit ventures. Nevertheless, one South African company
has developed a business model designed around open source
biotechnology software.
The company, Electric Genetics
Corporation, has released its bioinformatics software under a
free open source license and provides validation and support
services for a fee.64
Open source biotechnology projects are at various stages of
development. Some, such as the South African company and
the bioinformatics programming languages, have actual
products currently in use.65 Others, such as the HapMap
Project, are under way and moving towards their research
goals. Some, such as BIOS and the Public Patent Foundation,
are in the active planning and design phases. Still others are
in the early concept phase.

59. See the Open Bioinformatics Foundation web site at http://www.openbio.org for links to the languages and the relevant licenses.
60. See Open Bioinformatics Foundation, BioJava Project, at
http://www.biojava.org/download/binaries/LICENSE (last modified July 2,
2001).
61. See
GNU
Lesser
General
Public
License,
at
http://www.gnu.org/copyleft/lesser.html (last updated Nov. 27, 2000).
62. See id.
63. See id. For a list of other open source biotechnology projects, see
Cukier, supra note 17.
64. See Cukier, supra note 17. In 2002, the company organized a
“biohackathon,” flying scores of open source programmers to South Africa to
write code. Id. Kristen Philipkoski, Cure for South Africa’s Ills, WIRED NEWS,
Apr. 8, 2002, at http://www.wired.com/news/medtech/0,1286,51533,00.html
(last visited Sept. 6, 2004).
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B. OPEN SOURCE SOFTWARE: THE PREDECESSOR OF THE OPEN
SOURCE BIOTECHNOLOGY MOVEMENT
It is not surprising that the open source biotechnology
projects farthest along tend to have significant bioinformatics
elements. The open source biotechnology movement has its
roots in the open source software movement,66 and the easiest
transfer of principles occurs at the intersection of biology and
software where programs and databases are developed for
exploring and managing biotechnology information.67
66. For detailed discussions of the open source software movement, see
generally RICHARD STALLMAN, FREE SOFTWARE, FREE SOCIETY: SELECTED
ESSAYS OF RICHARD STALLMAN (Joshua Gay, ed., 2002); Marcus Maher, Open
Source Software: The Success of an Alternative Intellectual Property Incentive
Paradigm, 10 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 619 (2000) (tracing
the success of open source in software); Christian H. Nadan, Open Source
Licensing: Virus or Virtue?, 10 TEX. INTELL. PROP. L.J. 349 (2002) (advocating
open source as a great opportunity to commercialize and listing approaches for
businesses to take advantage of open source); Lawrence Lessig, The Limits in
Open Code: Regulatory Standards and the Future of the Net, 14 BERKELEY
TECH. L.J. 759 (1999) (suggesting that the open source movement will make it
more difficult for the government to regulate the Internet); Joseph Scott
Miller, Allchin's Folly: Exploding Some Myths About Open Source Software, 20
CARDOZO ARTS & ENT. L.J. 491 (2002) (rebutting the idea that open source is
bad for capitalism because it supports the underlying purpose of copyright by
disseminating information); Patrick K. Bobko, Open-Source Software and the
Demise of Copyright, 27 RUTGERS COMPUTER & TECH. L.J. 51, 90 (2001)
(arguing that open source software, by uncoupling the economic incentives
from the creative process, has “subvert[ed] the foundation upon which the
commercial software industry is built”); Mathias Strasser, A New Paradigm in
Intellectual Property Law?: The Case Against Open Sources, 2001 STAN. TECH.
L. REV. 4 (arguing that open source in copyright is flawed because it
undermines the incentive purpose of copyrights by exposing commercial
developers to too much risk); David S. Evans & Bernard J. Reddy, Government
Preferences for Promoting Open-Source Software: A Solution in Search of a
Problem, 9 MICH. TELECOMM. & TECH. L. REV. 313 (2003) (arguing that
software licensing is adequate thereby precluding any need for government to
get involved and impose open source); Klaus M. Schmidt & Monika Schnitzer,
Public Subsidies for Open Source? Some Economic Policy Issues of the
Software Market, 16 HARV. J.L. & TECH. 473, 488 (2003) (warning that open
source development may create “forking” so that different programs will not be
compatible with each other); Yochai Benkler, Coase's Penguin, or, Linux and
The Nature of the Firm, 112 YALE L.J. 369 (2002) (providing an interesting
study of how the open source movement defies Coase’s theory of organization,
which states that production must be organized by the market or managerial
hierarchy).
67. For a discussion of characteristics of the bioinformatics industry that
are either well-suited or ill-suited for the open source model, see generally
Open Source Genomics, Symposium on Bioinformatics and Intellectual
Property Law, 8 B.U. J. SCI. & TECH. L. 254 (2002) [hereinafter Symposium];
see also Maurer et al., supra note 1, at 33–35 (discussing the same set of issues
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The open source software movement is grounded in the
notion that end users should have the ability to study, change,
modify, and redistribute the software they use.68 Most software
is distributed in the form of object code, a series of ones and
zeroes that can be read by computers but is unintelligible to
humans, even skilled programmers.69 In order to modify the
software, a programmer needs the source code, which is a
compilation of the ones and zeroes found in the object code into
a language that can be understood by those skilled in the art of
programming.70 Without access to the source code, and the
authorization to change it, end users must depend on the
original software company to fix bugs, provide upgrades, and
modify the program for individual requirements.71 In the fastpaced and individualistic world of software programming such
an arrangement seems excruciatingly slow and insufficiently
attuned to the advantages of, and desire for, free intellectual
exchange.72
In contrast to this approach, open source pioneers
developed a different model in which source code is distributed
along with object code, and users are authorized to distribute
and modify the program toward their individual ends.73 The
most successful modifications are then reviewed and adopted
by the broader user community.
In many open source software projects, a group of
developers will operate loosely as project managers guiding the
incorporation of new code into the evolving program.74 Some
open source software programs have begun with a contribution
of software which is then provided to the community on terms
in relationship to open source biotechnology projects); Hope, supra note 26.
Although open source has flourished within the world of software
development, it has appeared in other disciplines as well. See Thomas Goetz,
Open Source Everywhere, WIRED MAGAZINE (Nov. 2003) (describing opensource-like
approaches
throughout
history),
available
at
http://www.wired.com/wired/archive/11.11/opensource.html.
One
commentator has suggested the following: “Coders, it could be argued, got to
open source first only because they were closest to the tool that made it a
feasible means of production: the Internet.” Id.
68. See Nadan, supra note 66, at 353.
69. See Joseph Scott Miller, Allchin's Folly: Exploding Some Myths About
Open Source Software, 20 CARDOZO ARTS & ENT. L.J. 491, 494 (2002).
70. See id.
71. See Nadan, supra note 66, at 353.
72. See STALLMAN, supra note 66, at 16.
73. See id. at 18, 20-21.
74. See Nadan, supra note 66, at 352.
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Other open
that allow modification and redistribution.75
software programs begin as little more than an idea, which
must then be developed into a project by the broader
programming community.76
A key problem for the open source software movement is
the challenge of ensuring that, after the source code is released
to the public, it remains available for future users to modify
and distribute. If developers simply renounce their copyrights
and release the code into the public domain, those who make
improvements would be able to make the improved version
closed and proprietary. For example, one who modifies the
original program by adding functionalities or fixing bugs could
claim to have created a derivative work based on a product in
the public domain.77 The second comer would then hold an
independent copyright on the derivative work and could
exercise that copyright by releasing the derivative program
solely in a closed proprietary fashion.78 If this happened, the
open source project could quickly degenerate. The best versions
of the program might be proprietary, and the software could
become closed.
Ensuring continued open access to the program requires a
creative twist on the notion of copyright protection. Rather
than releasing the information into the public domain, open
source developers retain their right to control the product,
exercising those rights only to the extent of trying to ensure
that the product remains open for modification and
distribution. For example, many open source software products
are licensed under the GPL, which requires, among other
things, that enhancements and derivatives must be made
available on the same open use and distribution terms as the
original software.79 This approach has been called “copyleft.”
75. See, e.g., Maher, supra note 66, at 623-24 (describing Netscape’s
Mozilla license which controls its formerly closed browser software); Lessig,
supra note 66, at 766 (noting Netscape’s contribution of its browser code to an
open source project).
76. See Maher, supra note 66, at 622-23 (describing the evolution of
Linux).
77. See Miller, supra note 69, at 495.
78. See id.
79. See Maher, supra note 66, at 638; GNU General Public License, at
http://www.fsf.org/copyleft/gpl.html (last visited Sept. 7, 2004). Other types of
open source licenses include the Berkeley Software Distribution License and
the
EFF
Open
Audio
License.
See
Open
Source,
at
http://www.opensource.org/licenses/bsd-license.php (last visited Sept. 7, 2004);
Electronic Frontier Foundation, at www.eff.org/IP/Open_licenses/eff.oal.html)
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The phrase reflects the notion that participants use the
copyright system, which normally operates to restrict the use of
works, in a manner that keeps works free from restrictions.80
The currency for those who participate in the open source
software movement is different from traditional economic
rewards. Programmers volunteer their time and ideas and
successful programmers are rewarded with prestige in the
programming community.81 In addition, prestige within the
programming community may translate into traditional
economic rewards in that programmers who demonstrate skills
in the open source community can trade on that reputation in
the job market.82 Other rewards include the satisfaction of
contributing to a body of knowledge and the joy of participating
in an intellectual exchange. One author describes these
phenomena in the following fashion:
Most who use and improve [open source software] do so with the hope
of making a unique and lasting contribution to the body of knowledge
or, in hacker terminology, coming up with a “cool” hack. For example,
only hours after Netscape had released the code for its Internet
browser, a group of Australian programmers “had attached a
cryptographic add-on” that enabled Netscape’s program to conduct
secure Internet transactions. The Australians “were paid handsomely
- but not with money. The programmers . . . got paid in respect from
the rest of the programming community and in the satisfaction of
turning out an elegant useful bit of software.”83

The wish to participate in, and contribute to, the
advancement of science may explain why individuals
participate in National Aeronautics and Space Administration’s
open source Mars project. The project, which is part of the
Mars mission, asks volunteer “clickworkers” to help identify
millions of craters and draw a map of the planet.84
Other rewards for participation in open source projects
may include the appeal of altruism.
For example, the
ThinkCycle project focuses on finding engineering solutions to
problems that plague underserved communities and the
environment.85 ThinkCycle, an academic nonprofit project, is
(last visited Sept. 7, 2004).
80. STALLMAN, supra note 66, at 20–21.
81. See Symposium, supra note 67, at 256; see, e.g., Maher, supra note 66,
at 631-33.
82. See Maher, supra note 66, at 632.
83. Bobko, supra note 66, at 83.
84. See Goetz, supra note 67.
85. See ThinkCycle, at http://www.thinkcycle.org/about (last visited Sept.
24, 2004).
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the brainchild of a group of Massachusetts Institute of
Technology students.86 It operates as an open source webbased design collaborative.87 Among other projects, ThinkCycle
has addressed a problem facing health care volunteers trying to
fight cholera. The challenge was to develop a kit to instruct
local people on the use and calibration of IV equipment.88
Easy-to-use systems cost $2,000 per patient, putting these
systems beyond the reach of most communities facing cholera
Less expensive systems were available but
outbreaks.89
required skilled workers to administer them. ThinkCycle
designed a system that cost $1.25 to manufacture and could be
Project volunteers
administered by unskilled workers.90
presumably were motivated at least in part by the intangible
rewards of helping desperately ill people in poor communities.
Although most open source software endeavors offer
intangible rewards to participants, not all eschew the more
traditional economic rewards. For example, some companies
have been built on the concept of providing peripheral products
and services to support the open source product. For example,
the Linux operating system was developed, and is expanded
and maintained in an open source, collaborative process. Red
Hat, Inc. provides software support services and easy-to-use
bundles of Linux for a fee.91 Red Hat did not develop the
software on which Linux operates nor does it employ the
programmers that maintain it.92 Red Hat does not control the
future development of Linux and cannot direct any
improvements made to it.93 Despite these limitations, Red Hat
has generated sufficient business to “win the approval of
financial markets and maintain [significant] market
capitalization.”94
In short, the desire to have software that can be freely
86. See id.
87. See Lee Ridgway, ThinkCycle: Reaching Out to Solve Real-World
Problems, 17 INFO., SERV. & TECH. THROUGHOUT MIT 3, at 1 (Jan./Feb. 2002),
available at http://web.mit.edu/is/isnews/v17/n03/170301.html.
88. See id. at 2.
89. See Goetz, supra note 67.
90. See id.
91. See Red Hat, at http://www.redhat.com (last visited Apr. 15, 2004); See
David McGowan, Legal Implications of Open-Source Software, 2001 U. ILL. L.
REV. 241, 242-43 (2001).
92. McGowan, supra note 91, at 242.
93. Id.
94. Id.
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understood, accessed, and modified has spawned cooperative
ventures in software development. Biotechnology researchers
are borrowing and adapting these approaches in efforts to
engage in collaborative research that can solve problems facing
poor communities, trim patent forests, and make the tools of
biotech innovation freely available.
Following the notion of copyleft, some of the open source
biotechnology projects use the power of the intellectual
property system to ensure that the technologies they develop,
and any future modifications, are no more restricted than the
original technology. In the biotechnology arena, however, the
intellectual property rights regime is frequently patent rather
than the copyright regime utilized in open source software.95
In the patent context, the patent holder exercises its patent
rights by requiring that those who use or modify the research
technology agree to maintain the open nature of the core
technology and any improvements.
II. PATENT MISUSE
A. WHAT IS PATENT MISUSE?
Patent misuse is defined as an impermissible attempt to
extend the time or scope of the patent grant.96 A patent is
intended to convey exclusive rights in an invention, but those
rights are limited by the twenty-year term of the grant and by
95. Copyright is not the exclusive rights regime for open source software,
nor is patent the exclusive rights regime for open source biotechnology.
Software can receive patent protection in some circumstances as well as
copyright protection. Compare 1 DONALD S. CHISUM, CHISUM ON PATENTS §
1.03[6][i], at 209 (2003) (explaining that some software is now patentable),
with Pamela Samuelson, CONTU Revisited: The Case Against Copyright
Protection for Computer Programs in Machine-Readable Form, 1984 DUKE L.
J. 663, 665 (1984) (noting that software in machine-readable form is
copyrightable). Similarly, to the extent that a biotechnology invention
includes software, the software may be eligible for copyright protection. In
addition, one scholar has argued that DNA sequences should be copyrightable
as well as patentable. See Irving Kayton, Copyright in Living Genetically
Engineered Works, 50 GEO. WASH. L. REV. 191 (1982). But see James G. Silva,
Copyright Protection of Biotechnology Works: Into the Dustbin of History?,
2000 B.C. INTELL. PROP. & TECH. Forum 012801 ¶3 (2000) (“[C]opyright
protection for biotechnology works is either impermissible or of severely
limited scope.”), at http://infoeagle.bc.edu/bc_org/avp/law/st_org/iptf/articles/
index.html; MICHAEL EPSTEIN, Protecting Biotechnology, in MODERN
INTELLECTUAL PROPERTY LAW 219, 230-31 (Supp. 1988).
96. See, e.g., Blonder-Tongue Labs., Inc. v. Univ. of Ill. Found., 402 U.S.
313, 343-44 (1971); 6 CHISUM, supra note 6, § 19.04, at 427.
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the boundaries of the invention that was created.
Acts that may constitute misuse include requiring patent
licensees to buy unpatented goods, prohibiting production or
sale of competing goods, and conditioning the license of one
patent on accepting a different license as well.97 The finding of
misuse rests on the notion that the patent holder is using its
rights to garner a return from something not in the patent.
The patent holder thereby improperly extends the scope of the
patent to things not included in the teachings of the patent
holder’s invention.
For example, in Zenith Radio v. Hazeltine,98 the Supreme
Court considered a package license in which the licensor would
not grant licenses to individual patents, but insisted on
granting licensees the rights to use any of the company’s 500odd patents in any of the licensee’s products for a five-year
term.99 The licensor reserved royalties on the total sales of the
licensee’s products regardless of whether the licensed patents
were used in the manufactured products.100 The Supreme
Court held that such coercive package licensing constituted
patent misuse.101 By requiring royalty payments on products
that did not incorporate any of the teachings of the patent, the
agreement impermissibly allowed the patent holder to extend
the scope of the patent beyond the invention specified in the
patent. 102 In other words, the patent holder was using its
patent to get a return on a product beyond what the patent
holder had invented.
A finding of patent misuse has serious implications for a
patent holder. If a patent holder is found to have engaged in
misuse, the patent is unenforceable until the misuse ends and
the effects of the behavior have dissipated.103 Until the effects
have dissipated, the patent cannot be enforced against any
97. See 6 CHISUM, supra note 6, § 19.04[3], at 451-534 (describing classic
acts of misuse).
98. 395 U.S. 100 (1969).
99. See Zenith Radio Corp. v. Hazeltine Research, Inc., 395 U.S. 100, 104,
133-34 (1969).
100. Id. at 134.
101. Id. at 139–40.
102. See id. at 135-36; 6 CHISUM, supra note 6, § 19.04[3][c], at 467-72
(discussing coercive package licenses).
103. See, e.g., C.R. Bard, Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1372 (Fed.
Cir. 1998) (“Patent misuse arises in equity, and a holding of misuse renders
the patent unenforceable until the misuse is purged; it does not, of itself,
invalidate the patent.”); 6 CHISUM, supra note 6, § 19.04, at 427.
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infringer, not just the one who brought the claim of misuse.104
The danger of a charge of patent misuse is amplified by the
relaxed standing rules of the doctrine, which date back to a
series of Supreme Court decisions in the 1940s.105 Under the
patent misuse doctrine, patent misuse can be raised as a
defense to infringement even if the defendant is not the one
who has suffered damage from the alleged misuse.106 As a
result, many parties may have standing to raise a claim of
patent misuse, a far wider group, for example, than those who
would have standing to raise antitrust violations as a
defense.107
The patent misuse doctrine emerged in the late nineteenth
and early twentieth centuries during the period in which state
and federal antitrust laws were taking hold.108 Patent misuse
and antitrust law share an intertwined history and intersect at
a variety of doctrinal points.109 Despite the intersections, a
defendant claiming patent misuse need not show a violation of
the antitrust laws.110
In addition, not all terms that appear to extend the time or
scope of the patent grant would constitute misuse. For
example, the Supreme Court has noted that although certain
104. 6 CHISUM, supra note 6, § 19.04, at 427.
105. See Morton Salt Co. v. G.S. Suppiger Co., 314 U.S. 488 (1942); Mercoid
Corp. v. Mid-Continent Inv. Co., 320 U.S. 661, 665-66 (1944); Recent
Decisions, Trade Regulation – Attempted Partial Monopoly of Unpatented
Product as Defense to Suit for Direct Infringement, 42 COLUM. L. REV. 882, 884
(1942).
106. See Mark A. Lemley, The Economic Irrationality of the Patent Misuse
Doctrine, 78 CAL. L. REV. 1599, 1610 (1990). See also Note, Is the Patent
Misuse Doctrine Obsolete? 110 HARV. L. REV. 1922, 1939 (1997) (arguing that
the more lenient standing requirement should be kept to maintain increased
judicial scrutiny of patents).
107. See, e.g., Ill. Brick Co. v. Illinois, 431 U.S. 720, 728-29 (1977) (holding
that only a direct purchaser, not others in the chain of manufacture and
distribution, may sue for antitrust damages under § 4 of the Clayton Act);
Duplan Corp. v. Deering Miliken, Inc., 444 F. Supp. 648, 699 (D.C.S.C. 1977)
(finding a misuse violation but not an antitrust violation because infringers
were not damaged by the patent holder’s improper actions); see generally
Albert R. Henry, Limitations Inherent in the Grant of Letters Patent, 27
CORNELL L. Q. 214, 235-36 (1942).
108. See Feldman, supra note 7, at 403.
109. For a general description of the development of patent misuse doctrine
and its intersection with antitrust doctrines, see id. at 402-31.
110. See, e.g., Morton Salt, 314 U.S. at 494; see also Va. Panel Corp. v. Mac
Panel Co., 133 F.3d 860, 872 (Fed. Cir. 1997) (noting that a violation of the
antitrust laws requires “more exacting proof than suffices to demonstrate
patent misuse”).
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extended payment agreements would bring a return beyond the
time of the grant, such arrangements would not constitute
patent misuse if they were reasonable business arrangements
entered into for the convenience of both parties.111 The line for
establishing whether behavior that appears to stretch the
temporal or substantive boundaries of the grant constitutes
misuse is unclear, however, and such questions presumably
would fall within a general analysis of what constitutes patent
misuse.
Over the last decade, the U.S. Court of Appeals for the
Federal Circuit has the doctrine of patent misuse, adding
elements and tests that mirror the federal antitrust laws.112
For example, the Federal Circuit has expanded the definition of
patent misuse by adding the requirement that the improper
extension of the time or scope of the patent must be “with
anticompetitive effect.”113 In addition, the Federal Circuit has
established that courts should use antitrust law’s rule of reason
test to determine whether a particular behavior constitutes
patent misuse.114 Thus, the Federal Circuit would test patent
misuse in general, and open source biotechnology licenses in
particular, by looking for anticompetitive effects under the
antitrust rule of reason.
The classic treatise on antitrust describes the rule of
reason as requiring a series of steps.115 First, the plaintiff has
the initial burden of showing that the behavior restrains
competition in a specific market. Second, if the plaintiff meets
this initial burden, the burden shifts to the defendant to show
that its behavior serves legitimate objectives. Third, if the
defendant meets that burden, the plaintiff may show that the
defendant could meet its objective using less restrictive
111. See Zenith Radio Corp. v. Hazeltine Research, Inc., 395 U.S. 100, 13637 (1969).
112. See Feldman, supra note 7, at 425-31; see also Robert J. Hoerner, The
Decline (And Fall?) of the Patent Misuse Doctrine in the Federal Circuit, 69
ANTITRUST L.J. 669, 672–673 (2002); Patricia A. Martone & Richard M.
Feustel, Jr., The Patent Misuse Defense – Does it Still Have Vitality?, in
INTELL. PROP. ANTITRUST 217, 250 (2002).
113. See Feldman, supra note 7, at 426; Mallinckrodt, Inc. v. Medipart,
Inc., 976 F.2d 700, 708 (Fed. Cir. 1992); Va. Panel, 133 F.3d at 869; C.R. Bard,
Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1372 (Fed. Cir. 1998); B. Braun Med., Inc.
v. Abbott Labs, 124 F.3d 1419, 1426 (Fed. Cir. 1997).
114. See supra note 113; see also Windsurfing Int’l, Inc. v. AMF, Inc., 782
F.2d 995, 1001-02 (Fed. Cir. 1986); Bayer AG v. Housey Pharms., Inc., 228 F.
Supp. 2d 467 (D. Del. 2002) (applying the Federal Circuit test).
115. Feldman, supra note 7, at 422 n.113.
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alternatives. And finally, the court must weigh the harms and
benefits of the restraint with the plaintiff bearing the burden to
show that the restraint is unreasonable on balance.116
I have argued that the Federal Circuit’s doctrine is
inconsistent with the relevant legislative and judicial
precedents, which suggest that patent misuse should be tested
by reference to patent policy, not antitrust law.117 In addition
to the dictates of precedent, using antitrust rules to test for
patent misuse will be inadequate because the policies
underlying patent misuse are not confined to limiting the types
of monopoly harms that antitrust law addresses.118 Thus,
rather than asking whether the effects of the behavior are
consistent with antitrust policy, courts should ask whether the
effects of the behavior are consistent with patent policy.119
B. THE PATENT MISUSE PROBLEM FOR OPEN SOURCE
BIOTECHNOLOGY
Open source biotechnology projects face the challenge of
keeping research tools and other inventions available to a
broad research community even as the technology advances.
Under ordinary principles of patent law, however, those who
make novel and nonobvious improvements in the core
technology would be entitled to apply for patents on their
improvements. This assumes, of course, that the advancement
meets all of the other requirements of patentability, including
utility, enablement, and patentable subject matter.
If
innovators patent their improvements, the best way of utilizing
the technology would then be controlled by multiple parties,
leading back to the problem of research techniques shrouded in
overlapping rights. As an added problem, any one of the
multiple parties could demand a royalty that places the full
technique beyond the reach of many who address the problems
of poor communities.
Open source biotechnology projects may face less risk from
subsequent innovators than open source software projects.
Biotech research tools frequently are protected by patents
rather than copyrights, and the standard for patentability is

116. See id.
117. Id. at 421.
118. Id. at 431.
119. For a more comprehensive discussion of the theories outlined below,
see Feldman, supra note 7, at 431–49.
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much higher than the standard for copyrightability.120 For
example, an improvement in a program that fixes a bug might
meet the standard for copyrightability as a derivative work but
not the nonobviousness standard for patentability.121 Thus,
one would expect open source biotechnology projects to face
fewer people who could claim rights to patentable
improvements on the technology than open source software
projects. Although the pool may be smaller, open source
biotechnology projects still face the risk that subsequent
improvers may claim patent rights to improvements. In
addition, to the extent that the biotech project includes
copyrightable elements, the project incurs the same risks as
traditional open source software.
Many of the open source biotech licensing agreements are
designed to avoid this problem by requiring that participants
agree to ensure that the core technology and any improvements
remain available on the same open terms as the core
technology. For example, the BIOS project requires that
participants grant back improvements in the core technology
and make such improvements freely available to others; the
HapMap project requires that users not file for patents for
information contained in the data base; and the BioJava license
requires that any patent license granted for a version of the
original software be consistent with the full freedom of use
specified in the license.122 Open source biotech projects,
120. See Mark A. Lemley & David W. O’Brien, Encouraging Software
Reuse, 49 STAN. L. REV. 255, 297 (1997) (“Because of the strong rights patent
law provides, the standards for obtaining a patent are higher than those for
obtaining a copyright or a trade secret.”).
121. Compare A. Samuel Oddi, An Uneasier Case for Copyright than for
Patent Protection of Computer Programs, 72 NEB. L. REV. 351, 384 (1993)
(noting that in order to qualify for patent protection, a computer program
must pass requirements for novelty, utility, and non-obviousness, while
copyright laws require only minimal originality), and 35 U.S.C. §§ 102, 103
(1988) (prescribing that the subject of the patent must be novel and
nonobvious), with Feist Publ'ns, Inc. v. Rural Tel. Serv. Co., 499 U.S. 340, 348
(1991) (holding in cases concerning copyrightability of phonebooks that choices
as to selection and arrangement, so long as they entail a minimal degree of
creativity, are sufficiently original that Congress may protect such
compilations through the copyright laws); Alfred Bell & Co. v. Catalda Fine
Arts, Inc., 191 F.2d 99, 102 (2d Cir. 1951) (holding that copyright protection
necessitates no large measure of novelty), and Philip Abromats, Nondisclosure
of Preexisting Works in Software Copyright Registrations: Inequitable Conduct
in Need of a Remedy, 32 JURIMETRICS J. 571, 574 (1992) (noting that in
copyright, the originality standard for derivative work is typically expressed
as simply requiring more than trivial additions).
122. See, e.g., BIOS Rockefeller Application, supra note 18; HAPMAP
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however, would not necessarily have to adopt this form of
licensing. For example, Maurer, Rai, and Sali’s Tropical
Disease Initiative does not envision that the project would file
for patents or restrict others in their ability to file for
patents.123
Open source biotechnology licenses may implicate the
patent misuse prohibition against extending the scope of the
patent to cover things beyond what the patent holder invented.
For example, when an open source license requires that any
improvements must remain freely available to others, the
patent holder is using the power of the patent granted on its
tool technology to reach an improvement, something not
contained in the original patent. Similarly, when the project
requires that users give the project a license to any
improvements, the patent holder again is using its patent
rights on the core technology to affect the disposition of
innovations not contained in the original patent.
The open source licensing scheme does not escape patent
misuse problems if the improvement is not itself independently
patentable. A patent holder can commit patent misuse by
reaching beyond its patent to unpatented technology as well as
patented technology.124 The core question is whether the
patent holder has reached beyond what it invented.
An open source approach in which users agree not to file
for patents on any information in the database would present
an interesting twist. If the information contained in the
database is completely in the public domain- that is, not subject
to patent protection- the group may avoid the problem of
misuse. There can be no patent misuse if the group does not
hold patent rights.
If, however, the group does hold patent rights and those
patent rights form part of the basis for the contractual
arrangement, patent misuse may be implicated. To the extent
that a patent holder uses its rights to restrict the disposition of
inventions not covered by the grant, the patent holder may be
PROJECT, supra note 1; Open Bioinformatics Foundation, BioJava Project,
supra note 60.
123. See Maurer, supra note 1, at 34.
124. Cf. Morton Salt Co. v. G.S. Suppiger Co., 314 U.S. 488 (1942); 1
HERBERT HOVENKAMP, ET AL., IP AND ANTITRUST: AN ANALYSIS OF ANTITRUST
PRINCIPLES APPLIED TO INTELLECTUAL PROPERTY LAW § 3.3b1(A), at 3-12
(Supp. 2003) (describing a classic patent misuse behavior in which a patent
holder requires that those who would license the patent also purchase a
separate, unpatented product).
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engaging in behavior that extends the scope of the patent grant
and thereby may be subject to a claim of misuse.
The open source arrangements that may implicate the
patent misuse doctrine fall into two general categories. The
first category includes agreements to grant the original patent
holder the right to use and sublicense any improvements to the
patented technology. The second category includes restrictions
on the terms on which the inventor of the improvement may
protect its invention. Such restrictions may take the form of
dictating the terms upon which the improvement may be
licensed or directing that the improvement may not be
patented.
In theory, licenses could cover not just improvements in
the core research technology, but also products invented using
the research technology. For example, one could imagine an
open source project grounded on the following principles: “We
will provide our research tools for you to develop a product that
can improve crop sustainability in underserved nations. If you
invent such a product, however, you must make it freely
available to others.” After all, what good would it do if the
project participants subsequently patented their discoveries,
making them available only to large agribiotech companies at
high prices? Such an arrangement would contemplate that
those granted free and open access to the research tools would
be required to grant free and open access to the things invented
with those tools.
Most open source projects have tried to steer clear of such
an expansive licensing arrangement, limiting their reach to
improvements made on the core research technology rather
than products invented using the technology. Nevertheless, the
implications are similar for both. In assigning rights to
inventions, the Patent Act does not distinguish between
inventions that are improvements on a prior invention and new
inventions.125 In both approaches, the patent holder is using
patent rights to affect the disposition of technology not within
125. See Gerald Sobel, The Antitrust Interface with Patents and Innovation:
Acquisition of Patents, Improvement Patents and Grant-Backs, Non-Use,
Fraud on the Patent Office, Development of New Products and Joint Research,
53 ANTITRUST L.J. 681, 689 (1985); see also Gen. Elec. Co. v. Wabash
Appliance Corp., 304 U.S. 364, 368-69 (1938) (noting that most inventions
represent improvements on some existing technology); see also Chiron Corp. v.
Genentech, Inc. 268 F. Supp. 2d 1148, 1155 (E.D. Cal. 2002) (noting that
“[p]atents are and should be granted to later inventors upon unobvious
improvements”).
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the patent. Therefore, both approaches suggest that the patent
holder is expanding the scope of the patent beyond its grants.
The question is whether the courts should consider such an
expansion improper.
One might wonder why the issue of patent misuse has not
arisen in the context of open source software. Software is
eligible for patent protection, and thus, patent software subject
to open source licenses could be subject to a charge of patent
misuse.126
Many of the intellectual property rights issues in open
source software have emerged as copyright rather than patent
issues.127 Although software can receive both copyright and
patent protection, copyright protection begins the moment the
software is fixed in a tangible medium of expression, while
patent protection requires a long and difficult application
process. Thus, if inventors of open source software do not
patent their works, there can be no charge of patent misuse.
In recent years, however, copyright has developed its own
doctrine of misuse. The doctrine is a relatively new addition to
the copyright landscape. No circuit court expressly recognized
the defense of copyright misuse until 1990 when the Fourth
Circuit decided Lasercomb America, Inc. v. Reynolds.128 The
court in Lasercomb found that a ninety-nine year noncompete
clause constituted copyright misuse in part because the clause
126. See Nadan, supra note 66, at 367-68 (noting that even if open source
licenses are binding, the copyleft provisions may not be enforceable in light of
the intellectual property misuse concepts including patent misuse); see also
Lawrence D. Graham & Richard O. Zerbe, Jr., Economically Efficient
Treatment of Computer Software: Reverse Engineering, Protection, and
Disclosure, 22 RUTGERS COMPUTER & TECH. L.J. 61, 93-94 (1996) (describing
the test for patentability of software).
127. See e.g., Nadan, supra note 66, at 369-71 (discussing copyright
concerns related to the GPL); Shawn W. Potter, Opening Up to Open Source, 6
RICH. J.L. & TECH. 24, ¶¶ 56-74 (Spring 2000) (detailing copyright concerns related to
open source software), at. http://www.richmond.edu/jolt/v6i5/article3.html.
128. 911 F.2d 970 (4th Cir. 1990); see David Scher, The Viability of the
Copyright Misuse Defense, 20 FORDHAM URB. L.J. 89, 91 (2000) (“Although the
misuse defense was discussed in the context of a copyright action in dictum as
early as 1948, the first court to employ the misuse defense to actually render a
copyright unenforceable was the Court of Appeals for the Fourth Circuit in
1990.”); G. Gervaise Davise, III, The Rapidly Growing Defense of Copyright
Misuse and Efforts to Establish Trademark Misuse, in INTELL. PROP.
ANTITRUST 639, 645 (PLI Intellectual Property Course Handbook Series No.
G-566, 1999); Aaron Xavier Fellmeth, Copyright Misuse and the Limits of the
Intellectual Property Monopoly, 6 J. INTELL. PROP. L. 1, 4 (1998) (“Until 1990,
no federal circuit court and only one federal district court accepted the
copyright misuse defense . . . .”).

144

MINN. J.L. SCI. & TECH.

[Vol. 6:1

would have denied the public the creative abilities of the
licensee and its staff for an excessive period of time.129
Lasercomb, considered the leading case on copyright
misuse, established a broad definition of copyright misuse,
similar to the equitable doctrine of unclean hands.130
Lasercomb’s definition of copyright misuse is generally
considered more expansive than the definition of patent
misuse, and there have been some efforts to narrow
Lasercomb’s broad definition.131 One might have expected that
challenges to the open source licensing structure would include
a charge of copyright misuse.132
The simplest answer is that there have been few cases
testing the validity of the licensing restrictions in the open
source software movement.133 As more cases emerge, open
source software licenses may indeed be challenged as patent or
copyright misuse.
III. ANALOGIES TO TRADITIONAL PATENT LICENSING
As described above, many of the arrangements used in
open source biotechnology projects could be characterized as
129. See Lasercomb, 911 F.2d at 978.
130. See Davise, supra note 128, at 645; Ilan Charnelle, The Justification
and Scope of the Copyright Misuse Doctrine and its Independence of the
Antitrust Laws, 9 UCLA ENT. L. REV. 167, 179 (2002) (noting that copyright
defense has its historical roots in the unclean hands defense, not in antitrust);
Atari Games Corp. v. Nintendo of Am. Inc., 975 F.2d 832, 846 (Fed. Cir. 1992)
(“In the absence of any statutory entitlement to a copyright misuse defense,
however, the defense is solely an equitable doctrine. Any party seeking
equitable relief must come to the court with ‘clean hands’.”); see also Alcatel
USA, Inc. v. DGI Technologies, Inc., 166 F.3d 772, 792 (5th Cir. 1999) (citing
Lasercomb, 911 F.2d at 792).
131. See Davise, supra note 128, at 645; see also Fellmeth, supra note 128,
at 27–28 (arguing that in general, the “rule of reason analysis is different
when applied to copyright misuse insofar as some courts construe
anticompetitive conduct with respect to copyrights more leniently than with
respect to patents”).
132. See Nadan, supra note 66, at 369 (discussing grantbacks and patent
misuse in the context of open source software).
133. See Dennis M. Kennedy, A Primer on Open Source Licensing Legal
Issues: Copyright, Copyleft, and Copyfuture, 20 ST. LOUIS U. PUB. L. REV. 345,
368 (2000); Cf. Nadan, supra note 66, at 368 (noting that the courts have yet to
analyze a copyleft provision for misuse). In 2004, one American and one
German case have addressed issues related to enforceability of the GPL. See
Computer Associates Int’l v. Quest Software, Inc., 333 F. Supp. 2d 688 (N.D.
Ill. 2004); GPL Gains Clout in German Legal Case, CNET NEWS, April 22,
2004,
available
at
http://news.com.com/2100-7344_35198117.html?part=business2-cnet.
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attempts to extend the scope of its patent beyond the grant.
The proper inquiry under such circumstances should be to
examine the effects of the behavior to determine whether such
an attempt is impermissible.
Open source biotechnology arrangements can be analogized
to three types of arrangements that have appeared in patent
licensing outside of the open source arena: field of use
restrictions, grantbacks, and reach-throughs. All three have
been alleged, under certain circumstances, to constitute
misuse.134
Precedents in these areas are few, and the logic is
frequently unsatisfying. In particular, courts often resolve
these cases by simply declaring that a behavior falls inside or
outside the patent grant. Thus, questions are resolved not by
looking at the extent of the invention and how far the behavior
reaches, but by concluding that it seems right to allow a patent
holder to engage in a behavior, so the behavior must surely fall
within the patent grant. The following section describes the
precedents in each of the three areas, exploring analogies to
open source licensing.
A. FIELD OF USE RESTRICTIONS
A field of use restriction places a limit on what licensees
can do with a patented product. Limits could include a
restriction on the type of product that a licensee can make with
a patented invention.135 For example, in Baldwin-Lima
134. See HOVENKAMP, ET AL., supra note 124, § 3.3b4, at 3-27 (describing
grantbacks); Bayer AG v. Housey Pharmaceuticals, Inc., 228 F. Supp. 2d 467
(D. Del. 2002) (concerning an allegation of patent misuse based on reachthrough royalties); see also Rebecca S. Eisenberg, Technology Transfer and the
Genome Project: Problems with Patenting Research Tools, 5 RISK 163, 172
(1994) (describing reach-through royalties); Principles and Guidelines for
Recipients of NIH Research Grants and Contracts on Obtaining and
Disseminating Biomedical Research Resources: Final Notice, 64 Fed. Reg.
72090, 72091 (Dec. 23, 1999) [hereinafter NIH Guidelines] (describing reachthrough royalties).
135. See Baldwin-Lima-Hamilton Corp. v. Tatnall Measuring Sys. Co., 169
F. Supp. 1, 30 (E.D. Pa. 1958) (finding the restriction outside the patent
grant), aff'd per curiam, 268 F.2d 395 (3d Cir. 1959). See also Turner Glass
Corp. v. Hartford-Empire Co., 173 F.2d 49, 53 (7th Cir. 1949) (finding no
antitrust violation when patentee leased glass-making machine under the
condition that it could be used only to make certain types of glassware); Barr
Rubber Prod. Co. v. Sun Rubber Co., 277 F. Supp. 484, 506 (S.D.N.Y. 1967)
(finding that holder of process patent could license one firm to use the process
for making hobby horses while denying this mode of use to other licensees),
aff’d 425 F.2d 1114 (2d Cir. 1970).
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Hamilton Corp. v. Tatnall Measuring Systems Co.,136 the patent
holder had invented a gauge to test the amount of stress effects
on a material.137 A manufacturer could make expendable
gauges that could be used as a tool to test different materials,
The gauges also could be manufactured as part of some other
machine or apparatus for constant monitoring.138 The patent
holder manufactured gauges for constant monitoring and
restricted licensees to making expendable gauges.139
Other limits are a restriction on the type of customers to
whom a licensee may sell, or a requirement that a licensee
restrict the uses that its customers can make of the product.140
For example, in General Talking Pictures v. Western Electric
Co.,141 licensees were permitted to sell patented amplifier tubes
only to those who manufactured products for private home use
but not to those who manufactured equipment for commercial
theaters.142
In general, courts have allowed field of use restrictions on
classes of customers to whom licensees can sell and restrictions
on the kinds of objects that the patented process may be used to
produce.143 At times, however, they have been willing to strike
down such agreements as illegal.144 The reasoning and results
are far from clear and consistent, and there have been no
Supreme Court decisions on field of use restrictions since the
136. 169 F. Supp 1, 30 (E.D. Pa.1958).
137. See id. at 28.
138. See id.
139. Id.
140. See Gen. Talking Pictures Co. v. W. Elec. Co., 304 U.S. 175 (1938),
aff’d on reh’g, 305 U.S. 124 (1938).
141. 304 U.S. 175 (1938), aff’d on reh’g, 305 U.S. 124 (1938).
142. See Gen. Talking Pictures, 304 U.S. at 180.
143. See United States v. Studiengesellschaft Kohle, 670 F.2d 1122, 1133
(D.C. Cir. 1981); see also 6 CHISUM, supra note 6, § 19.04[3][i], at 507
(describing how lower courts have upheld use and style restrictions).
144. See Studiengesellschaft Kohle, 670 F.2d at 1133.
The
Studiengesellschaft Kohle court noted the following:
Courts have generally followed General Talking Pictures in holding
legal such field-of-use restraints as a restriction on classes of
customers to which licensees could sell and a restriction on the kinds
of objects on which the process could be used. But courts have
occasionally distinguished General Talking Pictures and held the
restraint illegal where they perceived that the field-of-use restriction
was being used to extend the patent into areas not protected by the
patent monopoly, such as a requirement that a patented strain gauge
only be sold with the licensee's machines.
Id.
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1938 decision in General Talking Pictures.145 Commenting on
General Talking Pictures, the leading patent treatise notes that
the Court “seemed to uphold the legality of restricted use
conditions simply because they reflected a venerable practice
that had gone unquestioned for many years.”146 In addition,
the decision has been clouded by later Supreme Court cases
that could be read to implicitly overrule it.147
The confusion can be traced to a clash between the notion
that patent holders should be permitted to organize their
monopoly in an efficient manner148 and the first sale doctrine,
which holds that patent holders cannot control the use of a
patented item once it has been placed in the channels of
commerce. According to the first sale doctrine, the first
authorized sale of a patented article frees it from the patent
monopoly.149 Patent holders who try to restrain the use of the
patented article after the first authorized sale may be
exceeding the scope of the patent and are thereby subject to a
charge of misuse.150
The first sale doctrine traces its heritage to real property
doctrines as well as intellectual property doctrines. It is
grounded in theories of free alienability of chattel as well as the
view that individuals expect to be able to use the items they
purchase in any manner.151
In 1938, the Supreme Court faced a direct clash of the two
145. In the Supreme Court case of Automatic Radio Manufacturing Co. v.
Hazeltine Research, Inc., 339 U.S. 827 (1950), the parties challenged a
provision requiring that a licensee attach a notice to a product restricting its
use to private, educational, and non-commercial uses. See id. at 834-35. The
Supreme Court declined to address the question, however, ruling that the
issue was not properly before the Court. See id. at 835-36.
146. 6 CHISUM, supra note 6, § 19.04[3][i], at 507.
147. See id. § 19.04[3][i], at 510 (discussing General Talking Pictures and
its continued viability in the lower courts even though later Supreme Court
cases such as United States v. Univis Lens, 316 U.S. 241 (1942), have
implicitly overruled portions of the case by reaffirming the first sale doctrine
in the area of price-fixing).
148. See Ciba-Geigy Corp. v. Bolar Pharm. Co., 212 U.S.P.Q. (BNA) 712,
713 (E.D.N.Y. 1981) (“Ciba’s licensing practices may, as a practical matter,
have the effect of restricting the market . . . . This effect, however, is a direct
result of the HCT monopoly created by the 645 patent.”).
149. See 6 CHISUM, supra note 6, § 19.04[3][h], at 502.
150. See id. § 19.04[3][i], at 505.
151. See Cotton-Tie Co. v. Simmons, 106 U.S. 89 (1882); Patent Use
Restrictions, 75 HARV. L. REV. 602, 606 (describing the first sale doctrine as
applied in American Cotton-Tie and noting that the Court spoke in terms of
property law).
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issues in the case of General Talking Pictures152 In General
Talking Pictures, the patent holder held a patent on amplifier
tubes.153 Licensees were given the right to make the tubes, but
were only allowed to sell them for use in equipment designed
for homes. They were not given the right to sell them for use in
commercial movie house equipment.154 The Supreme Court
upheld the restrictions in a decision which it subsequently
reaffirmed with an additional opinion on rehearing.155
The facts presented two potential types of restrictions on
use after sale.
First, the patent holder arguably was
restraining the licensee’s use after proper purchase by telling
licensees that they could sell the tubes only to certain
customers. The Supreme Court, however, declared that the
patent grant embraces this type of restriction with no
discussion beyond the fact that the practice is an old one that
has never been questioned.156
Second, the licensing arrangement could be described as
limiting what the secondary buyers of the tubes could do after
purchasing them from the licensed manufacturer.
In
particular, secondary purchasers were effectively restricted to
using the particular tubes in home rather than commercial
equipment. Such a limit would restrict what a purchaser could
do once an item has been purchased in the ordinary channels of
commerce, in contravention of the first sale doctrine.
The Court’s language suggested that restrictions on what
the secondary purchaser does might have been problematic, but
that such was not the issue in this case. From the Court’s
perspective, the manufactured item had not passed
appropriately into the stream of commerce because its
manufacture was not permitted in the first place.157 The court
152. Gen. Talking Pictures Co. v. W. Elec. Co., 304 U.S. 175 (1938), aff’d on
reh’g, 305 U.S. 124 (1938).
153. See Gen. Talking Pictures, 304 U.S. at 176.
154. See id. at 180.
155. See Gen. Talking Pictures, 305 U.S. at 125-26. The rehearing opinion
appears to be crafted to avoid the question of whether later purchasers can be
restricted by a notice affixed to the product. See id. at 127 (“Nor have we
occasions to consider the effect of a ‘licensee’s notice’ which purports to restrict
the use of articles lawfully sold.”).
156. See id. at 127. The original decision offered no more discussion than
the rehearing. See Gen. Talking Pictures, 304 U.S. at 181 (stating simply that
“[t]here is no attempt on the part of the patent owner to extend the scope of
the monopoly beyond that contemplated by the patent statute”).
157. See Gen. Talking Pictures, 304 U.S. at 180–81; Gen. Talking Pictures,
305 U.S. at 127.
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reasoned that because the original licensee sold the product
outside the scope of the license, the effect was the same as if no
license whatsoever had been granted to the secondary buyer.158
Questions about restrictions on the secondary buyer simply
didn’t apply because the secondary buyer had no right to the
product at all.
In short, the court avoided application of the first sale
doctrine and held that a patent holder could restrict licensees
to manufacturing for a particular field of use. Little logic,
however, was provided for the decision. In addition, although
lower courts generally have followed General Talking Pictures,
some scholars have questioned its vitality given later Supreme
Court cases that implicitly overrule parts of the case by
reaffirming the first sale doctrine in the context of pricefixing.159
One lower court, however, distinguished General Talking
Pictures by finding a distinction between a patented machine
and patented components. 160 In United States v. Consolidated
Car-Heating,161 the patent holder had invented a metal alloy.162
The patent holder prevented licensees from using the alloy to
manufacture anything other than dental restorations, such as
crowns and dentures.163 The court found patent misuse,
essentially concluding that while a patent holder may restrict
the use its product is sold for under General Talking Pictures, a
patent holder cannot make that restriction when the product
will be used as a component in manufacturing something
else.164 Again, the court provided little explanation for the
decision.
Although the distinction may have been an attempt to
salvage the first sale doctrine, it makes little sense and does
not fit easily within the facts of the two cases. In General
158. See Gen. Talking Pictures, 305 U.S. at 127.
159. See 6 CHISUM, supra note 6, § 19.04[3][i], at 510 (questioning the
viability of General Talking Pictures in light of cases such as United States v.
Univis Lens, 316 U.S. 241 (1942)).
160. See United States v. Consol. Car-Heating Co., 87 U.S.P.Q. (BNA) 20,
21–23 (S.D.N.Y. 1950); 6 CHISUM. supra note 6, § 19.04[3][i], at 511 (describing
United States v. Consolidated Car-Heating and noting that to avoid General
Talking Pictures, the court drew a rather fine distinction between patented
machines and patented components and materials).
161. Consol. Car-Heating Co., 87 U.S.P.Q.(BNA) at 20.
162. Id. at 21.
163. Id. at 22-23.
164. See id. at 23.
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Talking Pictures, the licensee sold tubes for inclusion in
equipment. From a broad perspective, this could be considered
selling a component to be used in furthering manufacturing.
In 2004, the Federal Circuit waded into the question of
field of use restrictions in the case of Monsanto v. McFarling.165
The Monsanto case concerned Monsanto’s patented soybeans
seeds and the company’s single use restriction.166 Monsanto’s
soybean seeds have been modified by inserting a gene sequence
that makes the resulting plants immune from Monsanto’s
powerful Roundup herbicide.167 Monsanto requires that seed
companies who produce Monsanto’s seeds must execute license
agreements with farmers in which the farmers agree not to
replant any seeds harvested from the soybean plants.168 In
other words, the farmers may purchase seeds, use the seeds to
grow soybean plants, and sell the seeds from the soybean
plants for food, but not use the seeds from the soybean plants
for replanting. Monsanto brought an infringement suit against
a farmer who saved 1,500 bushels of soybean seeds from his
crop, enough to plant 1,500 acres the following year.169
Although the Federal Circuit upheld the single use
restriction, it found that the restriction could not be
characterized as a valid field of use restriction.170 The court
reasoned that the restriction did not place limitations on the
use of the product purchased under the patent, which could
have been valid.171 Rather, the agreement placed restrictions
on the use of the goods made with the licensed product, which
extended beyond the patent grant.172 In other words, Monsanto
sold first generation seeds that could be used to grow soybean
plants that make other seeds. Placing restrictions on what
could be done with the second generation seeds that had been
produced by the patented product would not be legitimate.
Although the restriction did not constitute a legitimate
field of use limitation, the court reasoned that the facts of the
case presented a unique set of circumstances that justified the
restrictions. Given that the second-generation seeds contain
165.
166.
167.
168.
169.
170.
171.
172.

363 F.3d 1336, 1339 (Fed. Cir. 2004).
See id.
See id. at 1338.
Id. at 1339.
See id. at 1339-40.
See id. at 1342-43.
See Monsanto v. McFarling, 363 F.3d 1336, 1342-43 (Fed. Cir. 2004).
See id.

2004]

OPEN SOURCE BIOTECHNOLOGY

151

Monsanto’s patented genetic sequence, the court found that
Monsanto held rights in the second-generation seeds as well.173
Thus, given that we must presume that Monsanto’s ‘435 patent reads
on the first-generation seeds, it also reads on the second-generation
seeds. Because the ‘435 patent would read on all generations of
soybeans produced, we hold that the restrictions in the Technology
Agreement prohibiting the replanting of the second generation of
ROUNDUP READY® soybeans do not extend Monsanto’s rights
under the patent statute.174

The court left open, however, what it saw as the more
difficult question of restrictions on the use of goods that are
made by the patented technology but do not incorporate it.175
Monsanto’s facts do present an interesting variation in that
most technology does not replicate itself in the way that living
organisms do. Technology generally is used as a tool to make
something else or as a component in making something else but
not to make a new version of itself, except perhaps in the case
of certain software applications in which code replicates itself.
In the Monsanto case, one can think of the creation of the
second generation seeds as the creation of a new product.
Perhaps restrictions can be applied to creation of a new
product, even if not to later sales.
Nevertheless, the facts of Monsanto can be analogized to
other, more common cases. The second generation seeds
contained Monsanto’s patented genetic sequence in the same
way that any time a patented product serves as a component;
the second product will contain the first. For example, the
dentures mentioned in Consolidated Car-Heating contained the
patented dental alloy. The court’s decision, therefore, could
suggest that any restriction on downstream products that
contain the patented product as a component will be
permissible, regardless of the first sale doctrine, because the
patent holder’s rights on making, using, and selling its product
would be implicated by the formation of a new product that
contains a patented element.
Such an approach would
significantly weaken the first sale doctrine.176
173. See id. at 1343.
174. Id.
175. See id. (“Our case law has not addressed in general terms the status of
such restrictions placed on goods made by, yet not incorporating, the licensed
good under the patent misuse doctrine. However, the Technology Agreement
presents a unique set of facts . . . .”).
176. The Monsanto opinion follows in the footsteps of an earlier Federal
Circuit decision that substantially weakens the first sale doctrine.
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Thus, Monsanto echoes the distinction suggested in
Consolidated Car-Heating but with the opposite result.
Monsanto would allow restrictions on downstream purchasers
and producers if the downstream products contain some
component that is patented. The court leaves open the
question of downstream products made with the patented
technology but not containing it.
One could argue that open source licenses are analogous to
field of use agreements. An open source license restricts the
use of the patented invention to a particular market, which is
the open source market. From this perspective, the patent
holder requires, for example, that its patented tool can only be
used to manufacture one type of product, and that type of
product is open source. Similarly, the patent holder requires
that its invention may only be used as a component of one type
of product. Again, that type of product would be an open source
product.
Under a similar analysis, one could describe open source
agreements as limiting the type of customer to whom a licensee
can sell. That customer would be one who operates within an
open source environment. As a variant of this, one could
analyze the agreement as requiring licensees to impose
restrictions on the types of uses customers can make of the
products made with the patented technology.
If the Monsanto approach were applied to open source
biotechnology, licensing restrictions relating to products that
contain the patented technology could escape the first sale
doctrine’s limitation on field of use restrictions. For example,
requirements that downstream versions of the software remain
available on open terms would be acceptable given that the
original software is a component of the downstream product.177
The question of whether restrictions on goods made with the
open source tool but not incorporating the tool would be
acceptable remains unresolved after Monsanto.
In summary, field of use restrictions are frequently upheld,
Mallinckrodt, Inc. v. Medipart, Inc., 976 F.2d 700, 708 (Fed. Cir. 1992).
177. Some have suggested that distinctions among different field of use
restrictions are irrelevant, although they do not necessarily agree on the
results of eliminating those distinctions. Compare Patent Use Restrictions,
supra note 151 (arguing for greater scrutiny of all field of use restrictions on
the grounds that they are basically anticompetitive), with Mallinckrodt, 976
F.2d at 705 (finding the distinction between restricting the use of first
purchasers and second purchasers to be formalistic line-drawing in a case in
which the licensing restrictions were upheld).
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although the cases lack a unifying logic. Courts tend to rely on
artificial distinctions between field of use restrictions that fall
within the grant of the patent and those that fall outside the
grant. As the first sale doctrine fades in Federal Circuit
jurisprudence, the legality of a field of use restriction for a
patented technology should focus more strongly on the general
test for patent misuse, examining the effects of the behavior.
The Federal Circuit may have had a similar approach in mind
in Mallinckrodt Inc. v. Mediapart178 when it suggested that a
first sale doctrine issue could be cast in terms of general patent
misuse inquiry which would then be tested either as a per se
violation or under the rule of reason.179 Such an approach
could mark the death knell for the first use doctrine, although
lessons learned from the doctrine could be addressed in the
context of the general patent misuse test. The question of
whether an open source license analogized to a field of use
restriction is permissible would then be tested either by asking
whether the effects of the behavior are inconsistent with patent
policy or by following the Federal Circuit’s current approach of
testing whether the effects of the behavior are inconsistent
with the antitrust rule of reason.
B. GRANTBACKS
Some open source licensing arrangements can be
analogized to grantback provisions. Grantback clauses require
the licensee to give the patent holder rights in products that
Grantbacks may include only
the licensee develops.180
improvements to technology that falls within the scope of the
original patent claims or may extend to all inventions within
the general subject matter of the patent.181
Some grantbacks are exclusive, thereby giving the patent
holder sole rights to any further invention. 182 The licensee who
invented the improvement may or may not have permission to
use the improvement as well, and that permission may or may
178. 976 F.2d 700, 708 (Fed. Cir. 1992).
179. See id. at 706-09.
180. See 6 CHISUM, supra note 6, § 19.04[3][j]; HOVENKAMP, ET AL., supra
note 124, § 3.3b4, at 3-27.
181. See 6 CHISUM, supra note 6, § 19.04[3][j], at 520.
182. Some exclusive grantbacks allow the second inventor to retain the
rights to use the improvement. See HOVENKAMP, ET AL., supra note 124, §
3.3b4, at 3-28–29 (describing different forms of exclusivity in grantback
agreements).
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In contrast, some
not require additional royalties.183
grantbacks are nonexclusive licenses, in which the original
patent holder presumably will be one of many licensees who
have permission to use the improvement.184 Again, the licensee
who invented the improvement may or may not be required to
pay additional royalties to use the invention.
Grantbacks in more limited form generally have been
upheld against claims of misuse.185 These provisions have been
structured primarily in two ways. First, the licensee grants the
original patent holder a royalty-free license to use the
improvement. In the alternative, the licensee assigns the
rights to the improvement back to the original patent holder
but reserves right to use the improvements at no additional
royalty.186
For example, in 1947, the Supreme Court considered a
patent misuse challenge to a clause requiring that a licensee
assign all improvements back to the patent holder, but
granting the licensee the right to use the improvements.187 In
this case, Transparent-Wrap Machine Corp. v. Stokes & Smith
Co.,188 the court held that the agreement extended beyond the
scope of the basic term of the patent but declined to find
misuse.189 The court rejected the argument that the clause
reduced the downstream inventor’s incentive to innovate,
reasoning that the licensee’s right to use the invention without
additional royalty created sufficient incentive for innovation.190
The court did note, however, that grantbacks could not be used
183. See Shelia J. McCartney, Licensing Alternatives to Limit Antitrust and
Misuse Exposure, 7 J. PROPRIETARY RTS. 10, 13 (1995); see also TransparentWrap Mach. Corp. v. Stokes & Smith Co., 329 U.S. 637, 646 (1947) (holding
that the licensee has the right to use the improvement at no additional
royalty).
184. See HOVENKAMP, ET AL., supra note 124, § 3.3b4, at 3-28–29
(describing different forms of exclusivity in grantback agreements).
185. See, e.g., Duplan Corp. v. Deering Milliken, Inc., 444 F.Supp. 648, 699700, (D.S.C. 1977), aff'd in part and rev'd in part, 594 F.2d 979 (4th Cir. 1979);
see also 6 CHISUM, supra note 6, § 19.04[3][j], at 525-26 (noting that limited
forms of grantbacks have been held not to constitute misuse); McCartney,
supra note 183, at 14 (1995) (concluding that although more limited forms of
grantbacks are unlikely to constitute misuse, some courts have found misuse
where the scope of the grantback is broader than the scope of the original
license).
186. See 6 CHISUM, supra note 6, § 19.01[3][j].
187. See Transparent-Wrap, 329 U.S. at 637.
188. 329 U.S. 637, 646 (1947).
189. Transparent-Wrap, 329 U.S. at 645-46.
190. Id. at 646.
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to suppress competition in violation of the antitrust laws.191
Subsequent to Transparent-Wrap, one lower court has
suggested that in determining whether a grantback clause
constitutes misuse, one should examine whether the clause
adversely affects the licensee’s incentive to engage in research
and development.192 In examining a misuse claim, the district
court in International Nickel Co. v. Ford Motor Co.193 noted
that grantback provisions that “tend to stifle research are
antagonistic to the underlying policies of the patent laws.”194
In applying this test, however, the International Nickel
court suggested that the licensee must provide specific evidence
that the clause actually stifled innovation, rather than merely
showing that the terms have the potential to stifle innovation.
For example, the court rejected the claim of misuse on the
grounds that considerable research had been conducted by
licensees. As a result, the court believed that “any claim that
absent the agreement, there would have been greater research
was mere conjecture.”195
Similarly, in Hull v. Brunswick,196 the Tenth Circuit
upheld a requirement that a licensee pay royalties on its
improvements.197 Given that no royalties were ever collected
on improvements, the court dismissed as merely hypothetical
the charge that the provision inhibited innovation.198 The court
noted in particular that the licensee never established any
instances in which innovation was actually inhibited.199
If potential impact on innovation were relevant, one would
have expected the Hull court to consider the deterrent effect of
the clause on the decision to innovate. At the very least, in the
first instance of an innovation, the innovator presumably would
not know that the clause would not be enforced. Even after the
patent holder has neglected to collect royalties on
improvements, a potential innovator still faces the risk that if
191. See id. at 646-47. Several lower court decisions in antitrust suits have
applied Transparent-Wrap to condemn grantbacks used to suppress
competition. See 6 CHISUM, supra note 6, § 19.04[3][j], at 520-26.
192. See Int’l Nickel v. Ford Motor Co., 166 F.Supp. 551, 565 (S.D.N.Y.
1958); Sobel, supra note 125, at 690-91.
193. 166 F. Supp. 551 (S.D.N.Y. 1958).
194. International Nickel, 166 F. Supp. at 565.
195. Id. at 566.
196. 704 F.2d 1195 (10th Cir. 1983).
197. Hull v. Brunswick Corp., 704 F.2d 1195, 1202 (10th Cir. 1983).
198. Id.
199. Id.
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an improvement were sufficiently substantial, the patent
holder might be moved to enforce its right to royalties, a risk
that at least has the potential to affect the decision to innovate.
Despite leniency on the issue of actual verses potential
incentive to innovate, some courts and commentators have
questioned the validity of more expansive grantbacks. For
example, one court held in 1977 that a grantback constitutes
misuse when the licensee is required to grant back
improvements related to technology beyond the original
innovation.200 The court described the patented innovation as
relating to a mechanism for arresting the twist of a particular
textile within a heating medium.201 A licensing provision
requiring that licensees grant back improvements related to
any technology, not just that related to the twisting within a
heating mechanism, reached too broadly and constituted patent
misuse.202
Other authorities have suggested that grantbacks may be
problematic if they are exclusive rather than nonexclusive.203
While nonexclusive grantbacks allow the market for the
improvement to thrive, exclusive grantbacks are more likely to
restrict competition relating to the improvement.204
Grantback provisions in open source biotechnology may be
structured as a nonexclusive grant of rights on improvements
in the core technology back to the open source project.205 This
form of grantback follows the outlines of the grantbacks that
200. See Duplan Corp. v. Deering Milliken, Inc., 444 F. Supp. 648, 699-700
(D.S.C. 1977), aff’d in part and rev’d in part, 549 F.2d 979 (4th Cir. 1979); see
also Transitron Elec. Corp. v. Hughes Aircraft Co., 487 F. Supp. 885, 893, 904
(D. Mass. 1980) (describing overbroad grantbacks as classic patent misuse and
citing Transparent-Wrap for the proposition that a license provision requiring
that the licensee grant back all its own patents to the licensor might constitute
patent misuse), aff’d 649 F.2d 871 (1st Cir. 1981); Sobel, supra note 125, at
690-91.
201. See Duplan, 444 F. Supp. at 699-700.
202. See id. at 700.
203. See HOVENKAMP, ET AL., supra note 124, § 3.3b4, at 3-27-28; U.S.
DEP’T OF JUSTICE AND FED. TRADE COMM’N, ANTITRUST GUIDELINES FOR THE
LICENSING OF INTELLECTUAL PROPERTY 5.6 (1995) [hereinafter FTC/DOJ
GUIDELINES]; NIH Guidelines, supra note 134.
204. See HOVENKAMP, JANIS, & LEMLEY, supra note 124, § 3.3b4, at A3-28;
FTC/DOJ Guidelines, supra note 203; NIH Guidelines, supra note 134.
205. See, e.g., Janet Hope, Open Source Biotechnology: My View on Open
Source
and
Pharmaceutical
Companies,
at
http://rsss.anu.edu.au/~janeth/OSBiotech.html; (last visited July 14, 2004); see
also Salleh, supra note 1, (noting that licensees will agree to share
improvements in the core technology).
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generally have been approved by courts and agencies.206 Open
source provisions that require an exclusive grant of rights back
to the group or that extend to products invented using the
patented technology would be more troubling.
Open
source
licensing,
however,
may
involve
considerations beyond those of ordinary grantbacks. Under
ordinary
circumstances,
nonexclusive
grantbacks
are
acceptable in part because although the improver must grant
rights to the original patent holder, the improver is also free to
grant rights to others. This freedom gives the improver room to
capitalize on the invention, at least with customers other than
the original patent holder. The ability to capitalize in this
matter may allay concerns that the grantback could inhibit the
licensee’s incentive to create improvements. The licensee is
always free to garner a return from customers other than the
original patent holder.
Such is not the case with open source licensing. In much
open source licensing, the licensee is required not only to grant
nonexclusive rights to the open source group, but also to license
others on the same open terms as the original license. Thus,
the improver may be unable to garner a return in any market.
Who would pay the improver when the improvement is
available for free from the open source project? This provision
could, in theory, effect incentives to improve the core
technology. As with field of use restrictions, however, the
relevant analysis for any particular form of grantback would
turn on whether the effects of the behavior are inconsistent
with patent policy or the antitrust rule of reason.
C. REACH-THROUGH PROVISIONS
Reach-through provisions have appeared most frequently
in the context of reach-through royalties on biotechnology
research tools.207 Under a reach-through royalty, payments for
206. See FTC/DOJ GUIDELINES, supra note 203, § 5.6; see 6 CHISUM, supra
note 6, § 19.04[3][j], at 525-26 (noting that courts generally have upheld
limited forms of grantbacks).
207. See, e.g., Eisenberg, supra note 134, at 172 (describing reach-through
royalties on sales of products that are developed in part through use of biotech
research tools); see Bayer AG v. Housey Pharm., Inc., 228 F. Supp. 2d 467, 471
(D. Del. 2002) (upholding a reach-through royalty on biotech research despite
allegations of patent misuse); see also NIH Guidelines, supra note 134, at
72,093 (expressing disapproval of reach-through royalties on biotech research
tools); see also John H. Barton, Research-Tool Patents: Issues for Health in the
Developing World, 80 BULL. WORLD HEALTH ORG. 121 (2002) (describing ways

158

MINN. J.L. SCI. & TECH.

[Vol. 6:1

use of a patented technology are measured in relation to
products created through a process involving the technology.208
For example, if the patented technology is a tool for isolating a
particular protein, a reach-through royalty might be structured
such that the licensee pays royalties based on a percentage of
sales from any drugs later developed to interact with the
protein. With a reach-through royalty, one could argue that
the patent holder is using rights granted in one technology to
garner a return on an invention not covered in the patent
grant.209
A similar issue arises with reach-through claims. With
reach-through claims, a broad enabling technology is patented
with claims drafted to cover things produced using that
technology.
The Federal Circuit recently rejected claims
drafted as reach-throughs.210
The legal status of reach-through royalties is unclear.
Only one case has addressed whether a reach-through royalty
constitutes patent misuse, and the court found no misuse.211 In
contrast, the National Institutes of Health guidelines strongly
discourage the use of reach-through royalties.212 In addition,
scholars have argued that reach-through royalties are
detrimental to the patent system because of the royalty
stacking effects and the tendency to discourage downstream
innovation.213 Again, to the extent that open source licenses
are analyzed as reach-throughs, the relevant analysis will be
whether the effects of the behavior are inconsistent with patent
policy or the antitrust rule of reason, depending on the rule
in which purchasers have tried to avoid reach-through royalties on research
tools), available at http://www.scielosp.org/scielo.php?script=sci_arttext
&pid=S0042-96862002000200007&lng=en&nrm=iso&tlng=en.
208. See Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter
Innovation? The Anticommons in Biomedical Research, 280 SCIENCE 698, 699
(1998).
209. See Feldman, supra note 7, at 439-49.
210. See Univ. of Rochester v. G.D. Searle & Co., Inc., 249 F. Supp. 2d 216,
235 (W.D.N.Y. 2003); see also Anne Y. Brody, Rochester v. Searle: Complying
with the Written Description and Enablement Requirements in Early-Stage
Drug Discovery, 22 BIOTECH. L. REPORT 472 (2003).
211. See Bayer, 228 F. Supp. 2d 467.
212. See NIH Guidelines, supra note 134, at 72,093.
213. See Barton, supra note 207, at 121; Eisenberg, supra note 134, at 172;
Feldman, supra note 7, at 442; Heller & Eisenberg, supra note 208, at 699; see
also Gene Patents and Other Genomic Inventions: Hearing Before the
Subcomm. On Courts and Intellectual Prop., House Comm. on the Judiciary,
106th Cong. 85 (2000) (statement of Dr. Harold Varmus, President and Chief
Executive Officer, Memorial Sloan-Kettering Cancer Center).
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applied.
IV. ARE THE EFFECTS OF OPEN SOURCE BIOTECH
LICENSING CONSISTENT WITH PATENT POLICY?
Many open source biotechnology licenses appear to extend
the scope of the patent to inventions beyond what is described
in the patent grant. The question is whether the expansion is
impermissible. One approach to testing whether open source
agreements are permissible is to examine whether the effects of
open source agreements are consistent with patent policy.214
The primary goal of the patent system is to promote the
progress of science for the benefit of the public.215 The system
is intended to foster the creation and disclosure of new
inventions, which will provide long-term benefits for society.216
In this context, the Supreme Court has noted “[t]he primary
purpose of our patent system is not reward of the individual
but the advancement of the arts and sciences. Its inducement
is directed to disclosure of advances in knowledge which will be
beneficial to society; it is not a certificate of merit, but an

214. See Blonder-Tongue Lab., Inc. v. Univ. of Ill. Found., 402 U.S. 313,
343 (1971) (noting that the Court has condemned attempts to broaden the
physical or temporal scope of the patent monopoly), remanded on other
grounds to 334 F. Supp. 47 (N.D. Ill. 1971), aff’d 465 F.2d 380 (7th Cir. 1972),
cert. denied 409 U.S. 1061 (1972); 6 CHISUM, supra note 6, at § 19.04
(discussing patent misuse).
215. See U.S. CONST. art. I, § 8, cl. 8; Kewanee Oil v. Bicron Corp., 416 U.S.
470, 480 (1974) (explaining that the patent laws carry out the Constitutional
mandate to “promote this progress by offering a right of exclusion for a limited
period as an incentive to inventors to risk the often enormous costs in terms of
time, research, and development”); Graham v. John Deere Co., 383 U.S. 1, 8-9
(1965) (citing Thomas Jefferson for the proposition that the patent monopoly
was not designed to secure to the inventor his natural rights to his discoveries
but rather as a reward or inducement to bring forth new discoveries); Sinclair
& Carroll Co., Inc. v. Interchemical Corp., 325 U.S. 327, 330-31 (1945) (stating
primary purpose of the patent system is to induce advancements in the arts
and science); cf. Mazer v. Stein, 347 U.S. 201, 219 (1954) ("[C]opyright law,
like the patent statutes, makes reward to the owner a secondary
consideration.") (internal quotation marks omitted), reh’g denied, 347 U.S.
949. But see Eldred v. Ashcroft, 538 U.S. 186, 212 n.18 (2003) (questioning
dissent’s analysis of the notion that reward of authors is a secondary
consideration in copyright law and arguing that end goals of the reward of
authors and progress of science are not mutually exclusive in that copyright
law serves public ends by providing individuals with an incentive to pursue
private ones), reh’g denied, 538 U.S. 916 (2003).
216. See Kewanee Oil, 416 U.S. at 480; Graham, 383 U.S. at 8-9; Sinclair &
Carroll Co., 325 U.S. at 331.
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incentive to disclosure.”217
To accomplish this ultimate goal, we grant patent holders
limited rights to exclude others from their invention, while
recognizing that such rights may create negative effects.218
Nevertheless, the current patent system strikes a balance
between the positive incentive effects that will redound to the
public benefit and any negative effects that the creation of
patent rights may produce.219 Positive and negative effects
should be evaluated on a system-wide basis, not according to
whether a particular arrangement would benefit the parties to
that arrangement.220
Within this context, open source licenses can be viewed as
consistent with patent policy. A patent delays the point at
which knowledge enters the public domain until the end of the
patent term. By ensuring that improvements and other
developments are immediately available, open source
accelerates the moment of dedication to public use. An
acceleration of the moment at which knowledge is brought to
the public domain is consistent with the goals of patent policy,
which are focused on obtaining new inventions for the public
benefit.221
On the other hand, one could argue that open source
clashes with the goals of the patent system by lowering the
available reward for downstream inventions. Although the
primary goal of the patent system is bringing forth knowledge
for the benefit of the public, the vehicle to accomplish that goal
is allocation of reward to inventors. If open source were to
lower overall incentives to downstream inventors, it could
217. Sinclair & Carroll Co., 325 U.S. at 330-31 (internal footnote omitted).
218. See Atl. Works v. Brady, 107 U.S. 192, 200 (1882) (discussing the costs
of granting patent monopolies and the importance of reserving patents only for
those inventors who make discoveries or inventions that are sufficiently
substantial); Robert P. Merges & Richard R. Nelson, On the Complex
Economics of Patent Scope, 90 COLUM. L. REV. 839, 868 (1990) (discussing
Kaplow, Gilbert, and Shapiro’s works on the subject).
219. For a more comprehensive analysis of the theory of patent rights and
the balance of positive and negative effects, see Feldman, supra note 7, at 43138.
220. See id. at 443, 448.
221. See, e.g., Kewanee Oil, 416 U.S. at 480 (patent laws create incentives
for inventors to engage in productive activities which “will have a positive
effect on society through the introduction of new products”); Graham, 383 U.S.
at 8-9 (patent monopoly induces inventors to bring forth new discoveries);
Sinclair & Carroll Co., 325 U.S. at 330-31 (patent system is designed to induce
advancements, which will be beneficial for society).
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reduce the amount of downstream invention in the long term,
which would be inconsistent with patent policy.
Such an analysis, however, fails on several levels. First, it
fails to properly measure the incentives offered in the open
source system. In the normal vision of the patent system, a
patent holder’s incentive and reward are measured by the level
of economic return. In an open source system, participants also
are motivated by non-economic factors such as a desire for
prestige and a desire to satisfy altruistic goals, including
serving those less fortunate and participating in the
advancement of science. An analysis that looks solely at
traditional economic rewards fails to capture the full dynamic
of the open source system.
If rewards such as altruism and prestige are sufficient
motivations for invention, however, one might ask why a patent
system is necessary in the first place. Wouldn’t the lure of
prestige, helping those less fortunate, and contributing to the
greater growth of science lure people into making inventions
such that there would have been no need for a patent system?
Without a patent system and an open source system, however,
the promise of non-economic rewards might be illusory. It
could be overshadowed by the ability of others to usurp
inventions through commercial exploitation. For example, I
could invent an application that increases crop durability, and
dedicate my invention to the public benefit. The dedication
would be fruitless, however, if others could improve or adapt
the invention and make those advancements proprietary. In
this way, downstream inventors reap economic rewards that
are in part derived from my inventions. The mechanism of
securing rights to produce those economic rewards interferes
with the dedication of my invention to the public good, which
would produce my altruistic reward. It is only the imposition of
open source agreements that preserves the integrity of the
altruistic reward, and it is only the patent system that permits
the development of open source.
Regarding the concern that open source may reduce
innovation, one could also argue that open source taps potential
innovation that the traditional free market cannot reach. For
example, those who participate in open source projects,
software or biotechnology, may do so in free time or in the type
of intermittent segments that do not lend themselves well to
commercial enterprise. From the perspective of the effects on
the overall patent system, one should consider that open source
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may harness untapped energy, thereby increasing society’s
overall innovative potential.
In addition, rather than simply arguing that open source
may reduce patent rewards, one should look at the overall
impact of open source to determine whether it undermines the
balances implicit in the patent system. In other words, one
must consider the effects of open source on the harms of the
current patent system as well as the benefits of the current
patent system.
Although open source biotechnology may reduce
downstream rewards if only traditional economic rewards are
measured, open source also reduces the harms side of the
equation. Open source cuts through patent thickets that
threaten to choke off innovation. In addition, open source does
not generate the kinds of monopolistic effects that the patent
system normally produces. Ordinarily, we tolerate the fact that
patent holders who have market power will increase price and
reduce supply during the patent term.222 This is part of the
necessary harms of the patent system. In contrast, given that
open source products are openly available for use, they would
not produce the same level of restriction of supply as one would
expect in the patent system.
There may, of course, be some restriction of supply with
open source as compared to a system with no intellectual
property rights. Use is restricted to those who agree to follow
the rules of the open source system, which may be a smaller
pool than those who would use the product if it were in the
public domain. Nevertheless, as a general matter, one could
expect open source to result in far greater usage than under a
traditional patent licensing arrangement.
There may be exceptions, however, to the rule that
traditional patent licensing will substantially restrict supply.
For example, a patent holder could choose to make its invention
broadly available on nominal terms. The Cohen/Boyer patent
for recombinant technology was reportedly licensed in broad,
nonexclusive agreements requiring relatively low royalty
222. See Arrow, supra note 14, at 617 (noting that patent rights produce
underutilization of information); Kesan & Banik, supra note 13, at 23-24
(noting that patents “impose social costs such as reduced levels of competition
or wasteful design-around efforts by competitors” but also create an incentive
to invest in research and development that leads to innovation); see generally
Merges & Nelson, supra note 218 (discussing the “complex economics of patent
scope”).
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payments.223 That invention and its licensing methods are
credited with spawning the development of the modern
biotechnology industry.224 The Cohen/Boyer patent, therefore,
demonstrates that licensing behavior that does not greatly
restrict supply is possible under traditional patent licensing,
even if it may be rare.
The Cohen/Boyer experience also provides insight into the
interplay between broad access and the patent system. First, it
serves as a reminder that broad access to technology can be
highly beneficial for encouraging innovation. In addition, the
Cohen/Boyer experience suggests that broad, cheap access is
not necessarily inconsistent with the patent system.
In short, although an open source system may reduce some
downstream economic rewards, an open source system
increases non-economic rewards and incentives. It may also
increase the level of invention exploiting untapped innovative
energy. Open source licensing also reduces the harms of the
current patent system by reducing patent thickets and avoiding
the short-term restriction of supply that one would expect
under traditional patent licensing. The ultimate effect of open
source licensing is to increase the supply of innovation and the
speed at which such innovation is available for the public
benefit. These effects advance the goals of the patent system.
V. ARE THE EFFECTS OF OPEN SOURCE BIOTECH
LICENSING CONSISTENT WITH THE ANTITRUST RULE
OF REASON?
Alternatively, one could test for patent misuse by
examining whether the effects of the behavior are
anticompetitive as measured by the antitrust rule of reason.
Although the current Federal Circuit misuse standard is
223. See David C. Hoffman, A Modest Proposal: Toward Improved Access to
Biotechnology Research Tools by Implementing a Broad Experimental Use
Exception, 89 CORNELL L. REV. 993, 1040-41 (2004) (explaining that the
Cohen/Boyer patents were licensed widely and nonexclusively to public sector
researchers with only minimal royalties assessed if a product made it to the
market and that as a result, their pioneering technology was successfully
transferred to the commercial sector without hindering the progress of basic
research).
224. See id.; Arti K. Rai & Rebecca S. Eisenberg, Bayh-Dole Reform and the
Progress of Biomedicine, 66 LAW & CONTEMP. PROBS. 289, 300 (2003) (noting
that “[m]any observers attribute the rapid progress of the biotechnology
industry to the fact that this technology was made widely available rather
than licensed exclusively to a single firm”).
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described nominally as distinct from antitrust law, antitrust
formulations infuse the analysis. In particular, the Federal
Circuit has held that to test for patent misuse, one should look
for anticompetitive effects through application of the antitrust
rule of reason.225 Even under a traditional patent misuse
analysis, as applied prior to the Federal Circuit’s shift, an
antitrust analysis can cast light on concerns that might be
shared by patent policy.226 One should consider, therefore,
whether open source biotech licensing would be consistent with
the antitrust rule of reason.
In the antitrust rule of reason, courts look for market
power, anticompetitive effects, and proof that the
anticompetitive
effects
outweigh
the
pro-competitive
A traditional challenge based on antitrust
benefits.227
principles also would have to establish that the open source
product and any downstream product constitute two separate
products. An improvement on core technology would be more
difficult to characterize as a separate product than something
invented using an open source research tool. Therefore, an
open source agreement that extends to products invented using
the research tool is more likely to be suspect under antitrust
law than an open source agreement that extends only to
improvements in the core technology.
As a starting point, an open source licensing arrangement
would not violate the antitrust rule of reason unless the open
source product had market power. Many open source products
would not have power in a properly defined market because
significant substitutes for their products would be available.
For example, the open source operating system Linux does not
have market power given the availability of other operating
systems such as Microsoft Windows.
If an open source group did have market power in a
particular product market, one could argue, nevertheless, that
the effects of the project are not anticompetitive within the
definition of the antitrust rule of reason. For example, the open
225 See supra note 113; see also Windsurfing Int’l, Inc. v. AMF, Inc., 782
F.2d 995, 1001-02 (Fed. Cir. 1986); Bayer AG v. Housey Pharms., Inc., 228 F.
Supp. 2d 467 (D. Del. 2002) (applying the Federal Circuit test).
226. See Feldman, supra note 7, at 425-30.
227. See Bd. of Trade of the City of Chi. v. United States, 246 U.S. 231, 238
(1918) (“Every agreement concerning trade, every regulation of trade,
restrains. . . . The true test of legality is whether the restraint imposed is such
as merely regulates and perhaps thereby promotes competition or whether it
is such as may suppress or even destroy competition.”).
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source arrangement could be characterized as extending
beyond the scope of the patent grant by affecting the market for
downstream goods. In other words, producers of downstream
goods would be restricted by the terms of the open source
license. A traditional antitrust rule of reason analysis would
focus on whether the open source group is dominating the
downstream market with the effect of reducing competition in
that market.
On the one hand, the open source group’s effects can be
characterized as reducing competition in the downstream
market. For example, consider the requirement that any
version of the core technology that contains downstream
improvements must be made available on open terms upstream
product. The behavior could be characterized as an attempt to
prevent the development of a downstream product, core plus
improvement, that is available on terms different from its own.
Such behavior potentially could be seen as reducing
competition in terms of reducing substitutes for the original
patent holder’s core products.228 Reducing competition for the
patent holder’s original product could be seen as
anticompetitive.
The open source group, however, is not trying to restrict
the amount of core plus improvement technology. It is acting to
maximize the amount of the improved technology available, by
ensuring that the improvements remain openly available. Such
an effect would be better described as ultimately increasing
rather than reducing the supply of the downstream product.
Moreover, to the extent one might argue that open source
licensing requirements discourage downstream innovation,
thereby reducing the supply of the downstream product, such
concerns would be outweighed by the pro-competitive benefits.
Open source licensing produces substantial pro-competitive
benefits, including the reduction of patent thickets and an
increase in the creation and dissemination of ideas without the
type of short-term restriction of supply associated with
traditional patenting license arrangements.

228. See, e.g., Dickson v. Microsoft Corp., 309 F.3d 193, 206-07 (4th Cir.
2002) (describing the potential for technology companies to try to dominate a
next-generation market to prevent the development of substitutes for its core
technology); Robin C. Feldman, Defensive Leveraging in Antitrust, 87 GEO. L.J.
2079, 2090-95 (1999) (arguing that leverage behavior should not be analyzed
solely as an attempt to reap additional monopoly profit from a second market
but also as an attempt to prevent erosion of the primary monopoly).
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Other traditional allegations of anticompetitive effects
could come in the form of a charge that the system resembles a
patent pool, the combination of which dominates the core
technology market itself.229 A patent pool is an agreement
between patent owners to aggregate intellectual property
rights.230 In simple pools, each party has the right to use all
technology in the pool without paying royalties.231 In more
sophisticated pools, members may pay royalties based on the
relative value of the technology they use or the pool may collect
royalties from third parties and distribute those royalties using
a schedule that reflects the significance of the technology
contributed.232
Patent pools may have anticompetitive effects because
pools may help participants coordinate price restraints or
market divisions.233 When parties who are in competition with
each other collude to restrain price or divide markets, the
behavior constitutes a per se violation of federal antitrust
law.234 In addition, patent pools may facilitate restraints of
trade in which the members of the pool coordinate to exclude
competition from other sources.235 Such restraints generally
would be tested under the rule of reason.236
Patent pools also may have pro-competitive effects. Patent
pools may reduce the transaction costs of negotiating rights
229. For a history and analysis of the treatment of patent pools under
antitrust law, see Steven C. Carlson, Patent Pools and the Antitrust Dilemma,
16 YALE J. ON REG. 359 (1999).
230. See Atif I. Azher, Antitrust Regulators and the Biopharmaceutical
Industry: Compulsory Licensing Schemes Ignoring Gene Therapy Patents’
Need, 25 U. PA. J. INT’L ECON. L. 383, 394 (2004); see also FTC/DOJ
Guidelines, supra note 203, at 28.
231. See Arti K. Rai, Regulating Scientific Research: Intellectual Property
Rights and the Norms of Science, 94 NW. U. L. REV. 77, 129 (1999).
232. See id.
233. See FTC/DOJ Guidelines, supra note 203, at 28.
234. See, e.g., id. (noting that when “pooling arrangements are mechanisms
to accomplish naked price fixing . . . they are subject to challenge under the
per se rule”); see also United States v. New Wrinkle, Inc., 342 U.S. 371, 380
(1952) (finding price-fixing in the context of patent cross-licensing).
235. See FTC/DOJ Guidelines, supra note 203, at 28 (noting access need
not be granted to all interested participants); cf. United States v. Singer Mfg.
Co., 374 U.S. 174, 194-95 (1963) (finding cross-license facilitated broader
scheme to exclude competitors).
236. See, e.g., Cont’l T.V. v. G.T.E. Sylvania Inc., 433 U.S. 36, 49 (1977)
(noting that the rule of reason is the prevailing standard for testing restraints
of trade), on remand to 461 F. Supp. 1046 (N.D. Cal. 1978), aff’d, 694 F.2d
1132 (4th Cir. 1982).
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when patents block each other or the costs of assembling the
rights necessary to engage in a particular form of research.237
They also may facilitate the exchange of scientific information.
A pooling arrangement could be challenged as patent
misuse if the pool dominated a particular market. Although
the holder of any one patent may not hold market power, the
group as a whole may have power when combining a number of
patents that would otherwise compete with each other. In
addition, it is possible that a pooling challenge to open source
licensing could be framed in the following terms: the relevant
market is not the market for an individual technology but the
market for the package of licenses necessary to engage in a
particular form of research. Within that market, the open
source project arguably dominates because no one else holds a
full package. Even if the open source project were analyzed as
a pool with market power, however, the project would not
necessarily violate the antitrust rule of reason. The pooling
challenge would be subject to the defenses described above that
the effects are not anticompetitive and that any anticompetitive
effects are outweighed substantially by the pro-competitive
benefits.
CONCLUSION
Open source biotechnology projects offer the scientific
community an opportunity to engage in collaborative research
in which the latest advancements in biotechnology are openly
available to a broad research community. The restrictions
necessary to maintain the open nature of such projects,
however, may implicate the doctrine of patent misuse in that
they appear to use the power of the patent grant to affect
inventions beyond the teachings of the original patent. The
proper analysis for determining whether a patent holder’s
behavior impermissibly extends the scope of the patent grant
turns either on whether the effects of the behavior are
inconsistent with patent policy or on whether the effects of the
behavior fail the antitrust rule of reason. Under either test,
however, open source projects should not constitute misuse.

237. See FTC/DOJ Guidelines, supra note 203, at 28; see also Azher, supra
note 230, 395-97 (discussing benefits of biotechnology pools).

